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ABSTRACT OF DISSERTATION
ANTISENSE AFP TRANSCRIPTS IN MOUSE LIVER AND THEIR POTENTIAL ROLE
IN AFP GENE REGULATION

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer,
ranking the sixth most common cancer and third most common cause of cancer mortality
worldwide. Alpha-fetoprotein (AFP) is a plasma protein that is highly expressed in the
fetal liver and shut off after birth. AFP expression is elevated in regenerating adult liver
and HCC and has been used extensively as a diagnostic marker of liver cancer. We
have been studying mouse liver gene regulation to better understand mechanisms by
which changes in gene expression contribute to liver development, homeostasis and
disease. Zinc Fingers and Homeoboxes 2 (Zhx2) has been identified as a repressor of
AFP, but the mechanism of this regulation remains unknown. Interestingly, all targets of
Zhx2 that have been identified to date, including H19, Glypican 3, Elovl3 and
Cytochrome P450 (CYP) genes, are also known to be misregulated in HCC. Thus, a
better understanding of the mechanism by which these genes are regulated by Zhx2 will
likely lead to new insights into gene regulation during HCC progression.
Antisense transcripts belong to a diverse class of long noncoding RNA molecules >200
nucleotides in length that often structurally resemble mRNAs, but do not encode
proteins. While studying AFP mRNA regulation by Zhx2 in the mouse, our lab identified
novel antisense AFP (asAFP) RNA transcripts that partially overlap the 3’ half of the
mouse AFP gene. ENCODE tracks of ChIP-seq data for histone modifications in mouse
liver show that the genomic region around the 5’ end of asAFP RNA has peaks for
marks associated with promoters and enhancers. To better understand asAFP
regulation, I identified the asAFP RNA 5’ end and the promoter elements that drive
transcription. asAFP RNAs are ~5kb alternatively spliced, mainly cytoplasmic transcripts
containing 2-4 exons. These transcripts were also detected in adult mouse liver RNAseq data. asAFP is likely a noncoding RNA because it contains several small open
reading frames that are 98 aa or smaller with no known functional domains or homology
to known proteins. There is no evidence for similar transcripts in human liver. The
abundance of asAFP RNA inversely correlates with AFP mRNA levels during postnatal
liver development. Normally, asAFP RNA levels are high and AFP mRNA levels are low
in the adult mouse liver. However, in the absence of Zhx2, AFP mRNA levels are higher
and asAFP RNA levels are reduced, suggesting asAFP may be involved in the
developmental regulation of AFP.
Antisense transcripts function through a variety of mechanisms to positively or negatively
regulate the expression of target genes. To explore the role of asAFP RNA in AFP gene
regulation, I expressed segments of asAFP RNA in a mouse liver cell line and measured
endogenous AFP mRNA levels. My data revealed that all segments of asAFP repressed
endogenous AFP mRNA in trans. To determine the mechanism by which asAFP RNA
regulates AFP, I expressed asAFP segments that overlapped only with exons or introns
of AFP. The asAFP segments that overlap with the exons showed greater repression of
endogenous AFP mRNA levels than those overlapping with intronic sequences.
Additionally, I considered whether asAFP RNA repression of AFP mRNA may involve

RNA editing by Adenosine deaminase acting on RNA (ADAR). ADARs convert
adenosine to inosine in double-stranded RNAs that results in RNA degradation. My data
indicate that AFP and asAFP dsRNA is not extensively edited, suggesting ADAR
mediated decay is not involved in the regulation of AFP mRNA expression. However,
further studies are required to determine the mechanism of cytoplasmic AFP mRNA
degradation. Together, my data characterizes the transcriptional regulation of novel
mouse asAFP transcripts and provides a model system to investigate how these
transcripts regulate AFP mRNA through RNA-RNA interaction.

KEYWORDS: Long Noncoding RNA, asAFP, AFP, RNA-RNA interaction, gene
regulation
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CHAPTER I
INTRODUCTION
The discovery of noncoding RNA transcripts and their involvement in gene
regulation has highlighted the complexity of the mammalian transcriptome. Only 2% of
the mammalian genome is transcribed into mature protein coding genes. Interestingly,
between 70% to 90% of the genome is transcribed into non-coding RNA (ncRNA)
transcripts with little or no protein coding potential, suggesting potential regulatory roles
in complex organisms (Wilusz et al., 2009). ncRNAs are grouped based on their
transcript size into two classes: small noncoding RNA (<200 base pairs (bp)) and long
noncoding RNAs (lncRNA, >200 bp) (Wilusz et al., 2009). Classical small noncoding
RNAs include microRNAs (miRNAs), Piwi-interacting RNAs (piRNAs), endogenous small
interfering (endo-si) RNAs, and some bacterial regulatory RNAs that are highly
conserved and are involved in various cellular processes (Cech and Steitz, 2014).
miRNAs have been the most extensively studied small noncoding RNA and are
posttranscriptional regulators of RNA stability or translation via extensive base pairing
(Cai et al., 2009)
Conversely, lncRNAs are a heterogeneous group of RNA molecules that are
greater than 200 nt in length, often resemble mRNAs, but lack protein coding potential.
(Quan et al., 2015; Yan and Wang, 2012). While the role of pervasive transcription of
the genome was not clear when first discovered, it was considered by some as
“transcriptional noise”. Yet, multiple stable lncRNA transcripts have been identified and
characterized in many organisms. LncRNAs have been shown to play important roles in
numerous cellular processes, including regulation of gene expression, genome
imprinting and dosage compensation. Despite the widespread attention lncRNAs have
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gained in recent years, it is not clear how many exist and whether uncharacterized
transcripts carry biological function and significance (Kung et al., 2013).
To better understand lncRNA’s role in liver gene regulation, this dissertation will
characterize the function of novel unannotated mouse antisense alpha-fetoprotein
(asAFP) RNA transcripts. The introduction will provide a general overview of long
noncoding RNAs, with a focus on the current understanding of natural antisense lncRNA
regulation, followed by a review of the AFP gene as a model biological system to study
liver gene regulation.

IDENTIFICATION of LONG NONCODING RNAs
H19 and X-inactive specific transcript (Xist) were among the first discovered
lncRNAs from searching cDNA libraries for other developmentally regulated and
genomic imprinted genes, respectively (Brown et al., 1992; Pachnis et al., 1984). As
expected, a number of genes were protein-coding, yet some transcripts were identified
as noncoding (Brannan et al., 1990; Brown et al., 1992). The development of high
throughput DNA tiling microarrays and next generation RNA-sequencing (RNA-seq)
analysis have expanded the number of identified lncRNAs (Yan and Wang, 2012).
Conventional cDNA microarray tiling studies provided the first glimpse of pervasive
transcription of non-coding RNAs by detecting transcripts represented by probes on the
array. From these studies, it was estimated that more than 70% of protein coding genes
have antisense partners that are expressed at lower levels (Faghihi and Wahlestedt,
2009; Katayama et al., 2005). Further advancements of sequencing technology led to
the development of next generation RNA-seq technology, which has become a widelyused tool that provides a more accurate and comprehensive view of the transcriptome.
RNA-seq studies revealed pervasive transcription of as many lncRNAs as protein coding
genes in the genome. Moreover, this technology highlighted lncRNA tissue specific
2

expression patterns and expanded the view of pervasive transcription of lncRNAs (Rinn
and Chang, 2012).
LncRNAs are a diverse class of transcripts that often share structural features
with mRNAs. Like mRNAs, they are generally transcribed by RNA polymerase II,
capped, polyadenylated, and spliced. However, not all lncRNAs exhibit these mRNA-like
features. The genes for lncRNAs, like those for mRNAs, are associated with chromatin
marks such as histone H3 lysine 4 trimethylation (H3K4me3) at their promoters and
histone H3 lysine 36 trimethylation (H3K36me3) throughout their gene body. These
histone modifications indicate evidence of active transcription. Many characterized
lncRNAs are preferentially localized in the nucleus, while some transcripts are exported
to the cytoplasm, where they exert their function. In comparison to mRNAs, lncRNAs, as
a class, are generally shorter in length, less stable, contain fewer exons and are poorly
conserved evolutionarily (Lee, 2012; Quinn and Chang, 2016; Zhang et al., 2014).
Because lncRNAs are often expressed at lower levels than protein coding genes and
display high tissue specificity, functional characterization of newly discovered transcripts
remains challenging (Zhang et al., 2014).
LncRNAs are called “noncoding” because they lack significant open reading
frames (arbitrarily defined as <100 amino acids) or homology to known protein domains.
Protein-coding genes are commonly defined by the presence of an ORF >100 aa.
However, a lncRNA may contain such an ORF by chance alone, and many wellcharacterized long ncRNAs (H19, Xist, and MEG3) do indeed contain longer ORFs
(Brannan et al., 1990; Brockdorff et al., 1992; Hagan et al., 2009; Joubel et al., 1996).
Various computational tools have been developed to search for predicted ORFs based
on genome alignment and homology to known proteins, such as NCBI Open Reading
Frame Finder (ORF finder) (Housman and Ulitsky, 2016). Additionally, algorithms such
as Coding-Potential Calculator (CPC) and Coding-Potential Assessment Tool (CPAT)
3

calculate coding probability based on sequence features such as ORF length, ORF
coverage, codon frequency, and the presence of sequences encoding known functional
domains (Kong et al., 2007; Wang et al., 2013b). These tools provide a general
approach to determine coding potential, but are limited in identifying new short proteins
that are <50 aa. Therefore, complementing these tools with experimental validation may
confirm whether a transcript is indeed noncoding.
Surprisingly, some lncRNAs were found to be associated with ribosomes.
However, it is still unclear whether any produced peptides are functional (Ingolia et al.,
2011). More recently, several groups have used ribosomal profiling as an approach to
answer this question. This technique stabilizes RNAs associated with ribosomes using
translation inhibitors, such as cycloheximide or emetine, followed by nuclease digestion
of RNAs not engaged with ribosomes. The ribosome-protected RNAs are purified and
analyzed by deep sequencing (Ingolia et al., 2011). Ingolia and colleagues performed
ribosome profiling experiments from mouse embryonic stem (ES) cells and found that a
significant number of lncRNAs had a ribosomal occupancy similar to known protein
coding genes. From these studies, they concluded that lncRNAs can be exported to the
cytoplasm and engage with ribosomes, but it was unclear whether these lncRNAs were
translated (Ingolia et al., 2011). A reanalysis of this same ribosome profiling data
focused on the 5’UTR and lncRNA ribosomal occupancy to distinguish between
lncRNAs and real coding sequences. During classical translation of protein coding
genes, once a ribosome encounters a bona fide stop codon, it results in an immediate
release and sharp decrease in ribosomal occupancy. However, when ribosomeassociated lncRNA’s encountered a stop codon, they remained engaged, instead of
falling off. This observation suggested that ribosome occupancy alone does not imply
protein/peptide synthesis (Guttman et al., 2013). Interestingly, some lncRNA have been
mistakenly classified as noncoding. For example, the tarsal-less RNA in Drosophila, was
4

previously thought to be a putative polyadenylated ncRNA (Tupy et al., 2005). In
subsequent studies, it was further characterized as a polycistronic mRNA that is
conserved among insects. Tarsal-less encodes multiple short, 33-nt ORFs, which are
translated into 11 aa functional peptides. These results further complicate the debate as
to whether lncRNA transcripts can encode functional proteins (Galindo et al., 2007;
Kondo et al., 2007; Kondo et al., 2010; Kung et al., 2013).

LncRNAS ARE FOUND THROUGHOUT THE GENOME
Genome-wide studies have revealed that much of the mammalian genome is
pervasively transcribed to produce noncoding and long noncoding RNAs (Cao, 2014;
Kung et al., 2013). LncRNAs can originate from intergenic, exonic, intronic, antisense or
enhancer regions (Figure 1-1). Long intergenic RNAs (lincRNA) are generally spliced
and polyadenylated transcripts transcribed by RNA pol II, from regions between genes
and do not overlap protein-coding genes (Brown et al., 1992; Hrdlickova et al., 2014)
(Bartolomei et al., 1991; Kung et al., 2013). Many lincRNAs were identified through
chromatin signatures of actively transcribed genes that are enriched with H3K4me3
marks at the promoter and H3K36me3 along the gene body (Kung et al., 2013).
Antisense lncRNAs are transcribed from the opposite strand of annotated, proteincoding genes or noncoding sense transcripts, with which they overlap. These transcripts
will be discussed in greater detail later in this chapter. Moreover, sense intronic or exonic
lncRNAs are transcribed in the same direction as their protein coding sense transcript. If
the TSS of lncRNAs that are located on the antisense strand of sense transcripts are
<1000 base pairs away from the TSS of protein coding gene, this may affect the
expression of their neighboring gene. Enhancer RNAs are generally bidirectionally
transcribed from DNA sequences of enhancer regions. Although lncRNAs have been
classified based on their genomic location in relation to nearby genes, it is not clear how
5

this classification reflects biological function or evolutionary origin (Hrdlickova et al.,
2014; Lee, 2012).
TRANSCRIPTIONAL REGULATION of LncRNAs
Like mRNAs, lncRNAs are mainly transcribed by RNA polymerase II (pol II) from
standard promoters that can be recognized by transcription factors (TFs) to form a
transcription initiation complex (Lin et al., 2015). Antisense RNAs also can originate from
independent, cryptic, shared bidirectional promoters, or divergent promoters that are
positioned within genes (Lin et al., 2015; Pelechano and Steinmetz, 2013). More
recently, enhancers have also been shown to direct the synthesis of lncRNAs (Kim et al.,
2010).
RNA pol II transcribed promoters contain DNA sequences that direct accurate
and sufficient initiation of transcription by the RNA polymerase II machinery (Butler and
Kadonaga, 2002; Juven-Gershon and Kadonaga, 2010; Smale and Kadonaga, 2003).
The core promoter can initiate transcription in a dispersed or focused manner. Dispersed
promoters are associated with CpG islands and encompass several weak transcriptional
start sites (TSS), whereas focused promoters contain a single predominant TSS or a few
TSS within a narrow region of several nucleotides. However, some promoters display
mixed focused and dispersed modes (Juven-Gershon and Kadonaga, 2010). Moreover,
promoters are enriched with chromatin features, such and H3K4me3 as indicators of
active transcription.
The RNA pol II core promoter is a structurally and functionally diverse region that
contains the minimal stretch of DNA sequences required to initiate transcription (Butler
and Kadonaga, 2002; Juven-Gershon and Kadonaga, 2010; Smale and Kadonaga,
2003; Theisen et al., 2010). Accurate and efficient transcription requires the action of
basal transcription factors that bind and recognize core promoter elements. The core
6

promoter contains the transcription initiation start site and may contain one or more key
regulatory elements that extend upstream and downstream, including TATA box, initiator
(Inr), downstream promoter element (DPE), and motif ten element (MTE) (Figure 1-2)
(Butler and Kadonaga, 2002). Each element has specific functions and can be present in
a variety of combinations to drive transcription (Butler and Kadonaga, 2002; JuvenGershon and Kadonaga, 2010; Smale and Kadonaga, 2003).
Some core promoters are TATA-dependent whereas others are considered
TATA-less. The TATA box was the first promoter motif found in eukaryotes and is
recognized by basal transcription factor for RNA polymerase II D (TFIID) complex,
including TATA box binding protein (TBP) and 13 TBP-associated factors (TAFs). The
TATA box consensus sequence (TATAAAG) lies about 30 bp upstream of the
transcription start site (TSS) and directs the preinitiation complex to the start site that lies
within the Inr element. The TFIIB recognition element (BRE) lies immediately upstream
and downstream of some TATA boxes and can either increase or decrease transcription
initiation in eukaryotes. Although TATA boxes are only present in ~20% of mammalian
core promoters such as N-myc gene and Igf2r (Igf2 receptor), many promoters do not
contain a TATA box but have other regulatory elements that drive transcription (Butler
and Kadonaga, 2002; Juven-Gershon and Kadonaga, 2010; Lin et al., 2015; Smale and
Kadonaga, 2003).
The Inr element is the most commonly occurring core promoter element and
contains the TSS. Some genes that are transcribed by TATA-less promoters contain
multiple TSSs (Lin et al., 2015). Transcription initiates within the Inr, in which the A
nucleotide is designated at the +1 position. Mutational analysis revealed sequences
spanning the -3 to +5 positions relative to the +1 position are necessary and sufficient for
accurate transcription (Smale and Kadonaga, 2003). However, an A at the +1 position is
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required for the strict spacing and functional requirements for the downstream MTE and
DPE promoter elements (Butler and Kadonaga, 2002; Juven-Gershon and Kadonaga,
2010; Theisen et al., 2010). The MTE is precisely located at +18 to +27 relative to A+1
and is important for basal transcription, but functions independently of a TATA box and
DPE (Lim et al., 2004; Theisen et al., 2010). The DPE element lies +28 to +32 bp
downstream of the Inr and is functionally similar to the TATA box in recruiting the
preinitiation complex to the TSS. Mutations in DPE element spacing relative to the A+1
results in 10-50-fold reduction in basal transcription activity (Butler and Kadonaga, 2002;
Juven-Gershon and Kadonaga, 2010; Kutach and Kadonaga, 2000). In summary, core
promoters are diverse and include multiple DNA elements that important for
transcriptional initiation and regulation.
Transcriptional regulation is not only achieved through the diversity of core
promoters, but also by enhancer elements. Transcriptional enhancers are cis-acting
DNA regulatory elements that positively regulate transcription of proximal promoters
over potentially long distances (Orom and Shiekhattar, 2011a). Enhancers bind general
and cell-specific TFs by DNA looping that interact with the promoter-bound
transcriptional machinery to activate expression (Melamed et al., 2016). Genome-wide
analysis of chromatin modifications suggests that promoters and enhancers may be
distinguishable based on their chromatin signatures (Koch et al., 2007). While active
promoters can be identified by H3K4me2, H3K4me3, H3K4me2 and H3K4me3, active
enhancers are identified by high levels of H3K4me1 and H3K4me2, low levels of
H3K4me3, and high levels of H3K27ac. Interestingly, both promoters and enhancers
occasionally display overlapping chromatin features, such as binding to RNA pol II,
H3K4me1, H3Kme3 and p300/CBP binding (Orom and Shiekhattar, 2011a, b). Although
the chromatin state at promoters are largely unchanged across diverse cell-types,
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enhancers have been shown to be associated with chromatin marks in a highly cell
specific manner (Heintzman et al., 2007; Orom and Shiekhattar, 2011a).
Recent genome-wide studies of transcriptional enhancers based on chromatin
modifications and enhancer binding proteins has identified of an emerging subclass of
lncRNAs that are transcribed bidirectionally from enhancer elements, called enhancerderived RNAs (eRNAs). eRNAs are synthesized from enhancers and are identified by
chromatin features, such as H3K4me1, H3K27ac and the presence of RNA pol II (Orom
and Shiekhattar, 2011a). A study in mouse neuronal cells following depolarization
identified transcription of short (<2kb), non-polyadenylated, non-coding, bidirectional
eRNA transcripts by mapping the regions associated with enhancer-specific
modifications bound by p300/CBP (Kim et al., 2010). eRNA transcription can be
bidirectional or unidirectional and their expression levels correlate with those of nearby
target genes (Kim et al., 2010; Orom and Shiekhattar, 2011a). A novel enhancer located
13.8 kb downstream the DHRS4-AS1 TSS was shown to produce an eRNA, AS1eRNA,
which increases DHRS4-AS1 expression by mediating a chromatin loop between the
enhancer and the DHRS4-AS1 promoter (Yang et al., 2016). To date the detailed
mechanism of eRNAs activity are ongoing; however, it is proposed that eRNAs may
facilitate looping of DNA sequences between enhancers and their target promoters or
they may regulate chromatin modifications that keep enhancers and promoters in their
active states (Melamed et al., 2016; Orom and Shiekhattar, 2011a).

ANTISENSE RNA REGULATES GENE EXPRESSION
Natural antisense transcripts (NATs) were initially discovered in bacteria and are
RNAs transcribed on the opposite strand of sense protein coding or noncoding genes
(Pelechano and Steinmetz, 2013; Wagner and Simons, 1994). The development of high-
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throughput gene expression analysis identified antisense transcripts widely distributed
throughout the mammalian genome in eukaryotes. Global transcriptome analysis
estimates that more than 30% and 70% of annotated transcripts in human and mouse,
respectively, have antisense transcripts that are noncoding (Katayama et al., 2005).
They can originate from the 5’ end, 3 end, or within the gene body of sense transcripts
(Faghihi and Wahlestedt, 2009; Lee, 2012).
Although a small portion of natural antisense lncRNAs have been characterized,
many more are unlikely to be transcriptional noise, but rather important regulators of
gene expression that can control transcription, epigenetic modification, chromatin
remodeling, RNA maturation, RNA transport, and protein synthesis (Figure 1-3)
(Hrdlickova et al., 2014).They can positively or negatively regulate the expression of
their overlapping sense transcript by forming sense-antisense RNA duplexes in the
nucleus and/or cytoplasm, suggesting a biological role for antisense RNAs. In the
nucleus, antisense RNAs can regulate their sense counterpart mRNAs by blocking
transcription, controlling epigenetic modifications, or modulating alternative splicing and
stability (Faghihi and Wahlestedt, 2009; Villegas and Zaphiropoulos, 2015; Zhang et al.,
2014). Several studies have demonstrated that when an antisense RNA overlaps with a
protein coding gene, the act of transcription in the antisense orientation, but not the
molecule itself, can interfere with the sense transcription through direct pol II
transcriptional interference in cis (Pelechano and Steinmetz, 2013). The transcription
collision model proposes that RNA polymerases on opposite DNA strands transcribing
towards each other physically crash and stall, blocking further transcription (Faghihi and
Wahlestedt, 2009; Pelechano and Steinmetz, 2013). For example, in budding yeast,
GAL10 and GAL7 are naturally organized in a tandem gene arrangement. To model the
effect of convergent and co- transcribed genes, the orientation of GAL7 was inverted in
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the sense orientation, while GAL10 was antisense. During the elongation process, the
synthesis of GAL7 halted as a result of synthesis from GAL10 in the antisense
orientation, thereby decreasing GAL7 expression (Prescott and Proudfoot, 2002).
Antisense RNAs may facilitate epigenetic changes by recruiting chromatin
remodeling complexes or nuclear proteins to specific genomic loci. The antisense noncoding RNA in the INK4 locus (ANRIL) is a 3.8kb transcript that is transcribed on the
opposite strand of the INK4A-ARF-INK4B gene cluster. ANRIL is transcribed by RNA pol
II and is spliced into several isoforms, most of which are polyadenylated (Kotake et al.,
2011; Villegas and Zaphiropoulos, 2015). The first intron of ANRIL overlaps with the two
exons of p15INK4B and was shown to be involved in epigenetic silencing of INK4b-ARFINK4a locus. ANRIL binds two polycomb repressor complexes, PRC1 and PRC2, which
are required for the silencing of p15INK48 tumor suppressor gene (Kotake et al., 2011;
Villegas and Zaphiropoulos, 2015; Yap et al., 2010).
There is evidence that antisense RNAs can regulate transcription of their sense
mRNA counterparts through the formation of antisense RNA:DNA hybrids. The
antisense intronic noncoding RASSF1 (ANRASSF1) is a capped, polyadenylated,
unspliced lncRNA that is transcribed on the opposite strand of the RASSF1A tumor
suppressor gene and overlaps exon 2 of RASSF1A. Through ectopic overexpression
and siRNA knockdown of ANRASSF1, this antisense RNA was shown to inversely
regulate RASSF1A mRNA and protein levels. The authors proposed that ANRASSF1
interacts with genomic DNA at the transcription site, forming an RNA/DNA hybrid, and
recruits the inhibitory PRC2 complex to the RASSF1A promoter region (Beckedorff et al.,
2013).
Nuclear sense-antisense RNA duplex formation can regulate gene expression
by modulating alternative splicing or altering mRNA localization or stability. Antisense
RNAs can influence splicing by masking splice sites, thereby blocking factors that would
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initiate splicing and altering the balance between splice variants. For example, the
thyroid hormone receptor alpha gene (TRα) encodes two protein isoforms, TRα1 and
TRα2, with antagonistic functions. The Rev-ErbA alpha (RevErbα) antisense transcript is
complementary to the last exon of TRα2 but not TRα1. Expression of RevErbα prevents
splicing of the TRα primary transcript, altering the balance of the two splice variants
(Faghihi and Wahlestedt, 2009; Hastings et al., 1997). Nuclear sense-antisense RNA
duplexes are also substrates for adenosine deaminases that act on RNA (ADAR) editing
enzymes that recognize double stranded RNAs (dsRNAs) and convert adenosines into
inosines. A- to-I editing often promotes nuclear retention in which single site mutations
can alter mRNA structure, expression and function. Several studies have identified many
editing sites to lie within inverted elements, specifically Alu repeats, or intronic
sequences. Peters, et al. demonstrated that the interaction between the antisense
transcript, sas-10 and the Drosophila melanogaster 4f-rnp induces A-to-I editing in the
overlapping region provides a potential mechanism for modifications of sense-antisense
RNA duplexes (Peters et al., 2003; Werner and Sayer, 2009).
LncRNAs that are exported to the cytoplasm can also form RNA duplexes with
complementary RNAs. They can regulate gene expression by modulating stability,
translation or by functioning as precursors of miRNA or compete for miRNA binding sites
(Yoon et al., 2013). Staufen 1 is known to bind double stranded RNAs and promote
mRNA decay. Staufen binding sites can be formed by imperfect base pairing between
an Alu element in the 3’UTR of a STAU1-mediated decay (SMD) target mRNA and
another Alu element in a cytoplasmic, polyadenylated lncRNA (1/2-sbsRNAs). 1/2sbsRNAs facilitate the binding of STAU1 to mRNA, thus promoting mRNA degradation.
However, not all mRNAs containing a 3’UTR Alu elements are targeted for SMD (Gong
and Maquat, 2011; Kim et al., 2005; Zhang et al., 2014).
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Antisense RNAs that promote mRNA stability is demonstrated by the antisense
transcript for β-secretase-1 (BACE1-AS). BACE1-AS is a conserved ~ 2kb spliced,
polyadenylated RNA that is transcribed on the opposite strand of the BACE locus.
BACE1-AS forms perfect base-pairing with 104 nucleotides of human BACE1 mRNA
exon 6. BACE1-AS transcripts promote the stability of BACE mRNA by masking the
binding site for miR-485-5p through the formation of sense-antisense RNA duplex, which
prevents BACE mRNA degradation (Faghihi et al., 2008; Faghihi et al., 2010).
LncRNAs can promote or inhibit translation of target genes. The human lincRNAp21 is transcribed in the antisense orientation ~15 kb upstream the Cdkn1a gene
(Huarte et al., 2010). lincRNA-p21 was recently shown to associate with ribosomes and
repress target mRNA translation. LincRNA-p21 was shown to base pair imperfectly with
CTNNB1 (β-catenin) and JUNB (JunB) mRNAs in several places throughout the coding
and UTR regions. The formation of RNA duplex and association with translation
repressor Rck and FMRP leads to translational repression of target genes (Yoon et al.,
2012; Zhang et al., 2014).
Previous genome-wide studies have predicted several lncRNAs as precursors of
miRNAs (He et al., 2008; Rashid et al., 2016). For example, H19 lncRNA exon 1 gives
rise to two conserved microRNAs, miR-675-3p and miR-675-5p that are induced during
skeletal muscle differentiation. Thus, H19 has an essential function in skeletal muscle
differentiation and regeneration that is mediated by miRNAs (Cai and Cullen, 2007; Dey
et al., 2014). Taken together, our understanding of the mechanistic details of antisense
RNAs biological function is ongoing, but many have been shown to act in cis or trans at
all levels of gene regulation and through a wide variety of mechanisms.
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LncRNA AND HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma (HCC) is the most common form of primary liver
cancer, accounting for 90% of cases (Huang et al., 2014). The highest incidences of
HCC cases occur in sub-Saharan Africa and Eastern Asia. However, HCC incidence in
the United States, United Kingdom, and Australia is increasing primarily due to cirrhosis
caused by chronic hepatitis B or C infections (HCV or HBV), excessive alcohol, obesity,
diabetes, and hemochromatosis (El-Serag and Rudolph, 2007). The rise of HCC in the
United States has been attributed to not only to HCV, but non-alcoholic fatty liver
disease (NAFLD), affecting up to 30% of adult population and 90% of those with morbid
obesity (Baffy et al., 2012).
LncRNA expression levels have been shown to be dysregulated in several
human cancers and to show tissue-specific expression (Huang et al., 2014). In HCC,
lncRNAs can contribute to HCC development and disease by influencing proliferation,
apoptosis, invasion, metastasis, and angiogenesis (Du et al., 2012; Huang et al., 2014;
Kung et al., 2013; Wang et al., 2011; Yu et al., 2015). As mentioned previously, lncRNAs
are involved in diverse biological processes including epigenetic silencing, splicing
regulation, RNA-miRNA, RNA-protein interactions and genetic variation (Huang et al.,
2014).
During embryonic development, the imprinted H19 lncRNA is expressed
abundantly in the liver, silenced after birth, and is frequently reactivated during
tumorigenesis (Poirier et al., 1991; Serviss et al., 2014). H19 dysregulation has been
observed in a variety of cancers, including HCC, colorectal, breast, and bladder cancers.
In some cases, increased H19 mRNA levels in HCC tumors were at higher levels than
the traditional HCC marker, AFP (Matouk et al., 2007). However, there are several
contradictory reports that suggest H19 functions as an oncogene or tumor suppressor.
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Matouk, et al. reported that H19 expression enhanced human HCC tumor growth and
formation in in vitro and in vivo models. They showed that hypoxia strongly upregulated
H19 RNA levels. When H19 expression was silenced in cells under hypoxic stress, they
failed to form colonies in soft agar after hypoxia recovery to the same level as H19expressing cells. Furthermore, silencing H19 expression significantly retarded tumor
growth in vivo, suggesting H19’s oncogenic phenotype (Matouk et al., 2007).
Conversely, loss and gain of function studies in HCC cells suggest that H19 functions as
a tumor suppressor. The suppression of tumor metastasis is proposed to be mediated by
the association of H19 and the hnRNP U/PCAF/RNA Pol II complex that activates miR200 family (Zhang et al., 2013). Further studies are necessary to clarify the molecular
mechanism(s) controlling the expression of the imprinted gene H19 and its role in tumor
development and metastasis.
Another lncRNA that has been reported to be dysregulated in HCC is highly
upregulated in liver cancer (HULC). HULC expression is upregulated in HCC tumors and
promotes hepatocyte proliferation via down regulation of the tumor suppressor gene p18
(Du et al., 2012). In another study, Wang, et al. discovered a self-amplifying, autoregulatory loop that upregulates HULC through the inhibition of miR-372. The expression
of HULC gene is upregulated in liver cancer cells by transcription factor cAMP response
element binding protein (CREB). HULC functions as a molecular decoy of miR-372
binding, thus activating its target gene, protein kinase cAMP-activated catalytic subunit
beta (PRKACB). This increase in PRKACB can induce the phosphorylation of CREB,
which in turn, stimulates HULC expression (Wang et al., 2010). Interestingly, HULC
expression levels have been detected in higher frequency in the plasma of HCC patients
when compared to healthy patients. These findings suggest that lncRNAs detected in
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plasma may serve as potential non-invasive biomarkers for the diagnosis/prognosis and
monitoring of disease progression (Xie et al., 2013; Yu et al., 2015).
The maternally expressed gene 3 (MEG3) lncRNA, which belongs to the
imprinted DLK1-MEG3 locus is a putative tumor suppressor in HCC and plays an
important role in cell development and growth (Qin et al., 2013; Zhou et al., 2012)
(Huang et al., 2014). MEG3 RNA levels were lower in four human liver HCC cell lines
and tissues in comparison to normal hepatocytes (Zhou et al., 2012). Braconi, et al.
demonstrated that MEG3 overexpression in HCC cells decreased cell growth (Braconi et
al., 2011; Huang et al., 2014; Yu et al., 2015). More importantly, MEG3 can significantly
increase p53 RNA and protein levels, triggering cell cycle arrest or apoptosis in
response to oncogene activation and other stress stimuli (Zhang et al., 2010).
Altogether, it is important to investigate the molecular mechanisms of lncRNA
expression in HCC to provide potential applications in diagnosis and treatment for liver
cancer.

AFP DEVELOPMENTAL AND GENE REGULATION
Alpha fetoprotein (AFP) was identified as the first oncofetal protein and is the
most commonly used serum biomarker for HCC (Abelev, 1971; Behne and Copur,
2012). AFP is a member of the serum albumin gene family that consists of Albumin
(Alb), Afamin (Afm), Vitamin D-binding protein (DBP) and AFP-related gene (Arg)
(Peterson et al., 2011). AFP is synthesized abundantly in the fetal liver and in the
visceral endoderm of the yolk sac and to a lesser extent the fetal gut, but is dramatically
repressed by 105 fold during the first several weeks after birth in mice (Belayew and
Tilghman, 1982). Postnatal AFP serum levels remain at low basal levels in normal adult
liver, but can be reactivated during liver regeneration and HCC (Abelev, 1971).
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The mouse AFP gene, located on chromosome 5, is regulated by four distinct
regulatory elements: a liver specific 250-bp promoter that is located directly adjacent to
exon 1 that contains multiple binding sites for transcription factors and three enhancers
(EI, EII, EIII) located further upstream at -2.5 kb, -5.0 kb and -6.5kb respectively. Each
300-bp enhancer is active in varying degrees in tissues where AFP is normally
expressed. EI and EII are active in all hepatocytes, whereas EIII activity is restricted to
hepatocytes surrounding the central vein (Peyton et al., 2000a). The 22kb mouse AFP
gene contains 15 exons, and encodes a 70 Da glycoprotein (Mizejewski, 2004; Peterson
et al., 2011). AFP is the most abundant serum protein in the developing mammalian
fetus and can bind a variety of ligands, including estrogen, bilirubin, fatty acids,
hormones, retinoids, steroids, heavy metals, dyes, dioxins and organic drugs, that could
allow it to modulate cell growth in the developing fetus (Mizejewski, 2004; Spear, 1999).
Much of the work to understand AFP gene regulation has been done in mice.
Olsson and Ruoslahti performed initial studies to understand the mechanisms of AFP
postnatal silencing by analyzing AFP serum levels in adult livers of 27 different inbred
mouse strains (Olsson et al., 1977). BALB/cJ mice expressed 20-fold higher AFP serum
levels compared to other mouse strains. The elevated serum AFP levels in BALB/cJ
mice were due to higher levels of steady-state hepatic AFP mRNA (Belayew and
Tilghman, 1982; Olsson et al., 1977). The phenotype for this post-natal persistence of
AFP mRNA levels in BALB/cJ mice was named raf (regulator of AFP), later named Afr1
(Alpha-fetoprotein regulator 1) (Belayew and Tilghman, 1982; Pachnis et al., 1984).
Linkage analysis initially mapped the Afr1 gene to mouse chromosome 15
(Blankenhorn et al., 1988). By positional cloning, Afr1 was identified as the Zinc-fingers
and homeoboxes 2 (Zhx2) gene that is responsible for the increased AFP levels in
BALB/cJ mice (Perincheri et al., 2005). The persistent expression of AFP in adult
BALB/cJ mice is due to a hypomorphic mutation in the Zhx2 gene, which contains an
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ETnIIα mouse endogenous retroviral element (MERV) in intron 1. Normal transcription
initiation of the Zhx2 gene in BALB/cJ mice occurs, however most pre-mRNAs splice into
the retroviral element, dramatically reducing expression of Zhx2.
A molecular screen for other genes expressed similarly to the developmental
regulation of AFP in adult BALB/cJ liver identified H19 as another Zhx2 target (Pachnis
et al., 1984). Low expression of Zhx2 in adult BALB/cJ mice correlated with increased
expression of liver AFP and H19 mRNA levels compared to wild-type mice. Further
studies showed that the expression of a Zhx2 transgene driven by a liver specific
transthyretin enhancer/promoter restored wild-type Zhx2 expression in BALB/cJ mice
and repressed AFP and H19 mRNA, providing further evidence that Zhx2 is involved in
the postnatal silencing of AFP and H19 in the adult liver (Perincheri et al., 2005).
Moreover, Zhx2 mRNA levels increase while AFP mRNA levels decrease after birth in
wild-type mice, consistent with Zhx2’s role in AFP mRNA repression (Jiang et al., 2017).
These data suggest that Zhx2 functions as a repressor of target genes in the liver and
the reduced Zhx2 levels in BALB/cJ livers leads to increased postnatal expression of
these genes.

ZINC FINGER AND HOMEOBOXES 2 (Zhx2)
Zinc fingers and homeoboxes 2 (Zhx2) is a member of a small family of highly
conserved vertebrate-specific transcription factors that include Zhx1 and Zhx3. The Zhx
family share similar gene structure in which the proteins are encoded by an unusually
large internal exon. Each Zhx protein contains two amino terminal C2-H2-type zinc
fingers and four or five homeodomains, protein domains typically associated with DNA,
RNA, and protein interactions, suggesting that these proteins may function as
transcriptional regulators. Analysis of mouse Zhx mRNAs by Northern blot revealed that
these transcripts are expressed ubiquitously and levels vary among different tissues.
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Zhx1 and Zhx2 are tightly linked on mouse chromosome 15, whereas Zhx3 is located on
chromosome 20. Each Zhx family member forms homodimers and heterodimers with
each other and NF-YA and luciferase assays suggest that ZHX proteins function as
transcriptional repressors (Kawata et al., 2003a; Kawata et al., 2003b).
Transgenic mouse studies showed that Zhx2 acts through the 250 bp AFP
promoter; however, it is not known if this is a direct or indirect interaction (Peyton et al.,
2000a). Zhx2 is considered as a repressor of developmentally regulated genes including
AFP, H19, Glypican 3 (GPC3) and Lipoprotein lipase (Lpl) (Gargalovic et al., 2010;
Morford et al., 2007; Pachnis et al., 1984). Interestingly, all these Zhx2 targets are also
mis-regulated in HCC. More recently, in contrast to previously identified Zhx2 targets
that appear to be repressed by Zhx2, cytochrome P450 (CYP) enzymes and the mouse
major urinary proteins are positively regulated by Zhx2 (Creasy et al., 2016; Jiang et al.,
2017). Creasy, et al. performed gender specific studies using conditional Zhx2 deletion
in mice and demonstrated that Cyp2a4 expression in adult male liver increased in the
absence of Zhx2 (Creasy et al., 2016). In another study, Zhx2 was shown to bind the
Mup24 promoter and is required for normal levels of Mup expression in the adult liver;
BALB/cJ mice have abnormally low levels of Mup expression (Jiang et al., 2017). Taken
together, these data indicate Zhx2 may positively or negatively regulate target genes;
however, the exact mechanism by which Zhx2 regulates AFP and other target genes is
not fully understood.

19

Figure 1-1. Long non-coding RNAs are found throughout the genome. LncRNAs are
defined based on their genomic location relative to nearby protein-coding genes.
Intergenic lncRNAs are located in between genes and do not overlap nearby protein
coding genes. lncRNAs that are bi-directionally transcribed include enhancer RNAs
synthesized from enhancer regions or located on the opposite strand; their transcription
start sites (TSS) lie close to the TSS protein of coding sense transcripts. Exonic and
Intronic sense lncRNAs share exons or introns with, and are transcribed in the same
direction as, the protein coding genes. Antisense RNAs are found on the opposite
strand and can completely or partially overlap nearby protein coding genes.
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Figure 1-2. RNA pol II core promoter elements. RNA Pol II promoters contain a set of
core DNA elements that can be present in a variety of combinations to facilitate
transcription. Some promoters contain a TATA box that lies about 30 bp upstream of the
transcription start site that directs the preinitiation complex to the TSS, which lies within
the Initiator (Inr) element. The TFIIB Recognition elements (BRE) that lie upstream and
downstream the TATA box can either increase or decrease transcription rates in
eukaryotes. The Initiator element contains a consensus sequence where the A is at the
+1 position. In TATA-less promoters, the downstream promoter elements that are
dependent of the Initiator include the motif ten element (MTE) Downstream Promoter
element (DPE). The MTE is precisely located at +18 to +27 relative to A+1 in the Inr. The
DPE element lies at +28 to +33 bp downstream of the Inr and is functionally similar to
the TATA box in directing preinitiation complex to the TSS. Adapted from (Butler and
Kadonaga, 2002)
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Figure 1-3. Antisene RNA regulation of gene expression . Antisene RNAs can regulate
gene expression by modulating transcription, RNA processing, and/or translation.The act
of transcription in the antisense orientation can modulate transcription of sense RNA as
in the case of transcriptional interference, when RNA polymerases from both strands
collide in the overlapping region, thus blocking transcription. Antisense RNAs may
modulate epigenetic regulation through DNA methylation or by recruiting chromatin
modifying complexes to activate or repress gene expression. Postranscriptionally,
antisense RNAs can bind to the overlapping sense transcript and mask splice sites
resulting in alternative splicing. The formation of nuclear sense-antisense dsRNAs may
serve as substrates for RNA editng enzymes, thereby altering nuclear mRNA retention,
stability and transport. The formation of cytoplasmic sense-antisense RNA duplex can
alter mRNA stability by masking miRNA binding sites or by Staufen-mediated decay.
Alternatively, antisense RNAs can alter translation by physical interaction with the
translational machinery or binding to sense transcripts, thereby blocking
intiation/elongation or ribosomal entry.
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CHAPTER II
MATERIALS AND METHODS
Mice
Mouse liver RNA samples used in this dissertation were obtained from mice that were
housed in the University of Kentucky Division of Laboratory Animal Research (DLAR)
facility and kept according to Institutional Animal Care and Use Committee (IACUC)
approved protocols. I obtained tissues or RNA from others in the lab for my analyses.
Several types of mice with altered Zhx2 expression were used. The TTR-Flag-Zhx2
transgenic mice express a liver-specific tagged Zhx2 protein on a BALB/cJ background.
Zhx2 protein levels in the transgenic animals are similar to wild-type mice. Liver RNA
was prepared from BALB/cJ littermates with or without the transgene. Wild-type Zhx2
(Zhx2 +/+), liver-specific knock-out (Zhx2 Δhep) or whole-body Zhx2 knock-out (Zhx2 -/-)
littermates on a C57/Bl6 background in which the Zhx2 gene had been deleted by Cre
recombinase were also used in some experiments. These mice have been described
previously (Creasy et al., 2016; Jiang et al., 2017).
For the liver tumor model, male C3H/Bl6 livers were harvested 36 weeks after a
single DEN treatment. These samples have been described previously (Creasy et al.,
2016).
5’ Rapid Ampliﬁcation of Complementary DNA Ends (RACE)
5′ RACE was performed using a 5′/3′ 2nd Generation RACE kit (catalog no.
03353621001; Roche Applied Science) following the manufacturer's instruction. Briefly,
1ug of purified total RNA from BALB/cJ mice that express a liver-specific Zhx2 transgene
was reverse transcribed by (SuperScript™ II) using RT primer #725 (see Table 2-1 for
all the oligos used in this thesis). The resulting cDNA was purified using the PCR
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cleanup kit (Promega), and a homopolymeric (dA) tail was added at the 3′ end of the
cDNA (corresponding to the 5’ end of the RNA) using terminal transferase. The (dA)tailed cDNA was amplified by PCR using the provided forward oligo (dT)-anchor primer
and the gene-specific reverse primer #760. Finally, the resulting PCR product was used
as a template to generate a nested PCR product using the provided anchor primer and
another gene-specific reverse primer #396. The final PCR product was cloned in pGEMT-Easy vector (Promega). Following bacterial transformation, colony PCR (primers #386
and #387) was performed to screen individual clones for the presence and size of the
insert. Minipreps were prepared for plasmids with various sized (400bp, 550bp, 600bp,
and 1kb) inserts and sequenced (ACGT). Only 5’RACE clone #7, with a 400 bp insert,
corresponded to the AFP gene locus. The remaining 5’ RACE clones were either found
on a different locus or were repetitive elements.
A second nested PCR reaction was performed to identify additional 5’ RACE products
using the provided anchor primer and two independent gene-specific reverse primers:
#824 and #726. However, after cloning and sequencing additional fragment, no
additional clones from the AFP locus were found.
A second 5’ RACE reaction was performed with the previously described cDNA and
amplified by PCR using the provided forward oligo (dT)-anchor primer and three different
gene-specific reverse primers #835, #831, and #776. From this, two additional clones
that matched the previously identified 5’ RACE clone #7, but contained sequences that
did not align to AFP gene locus at the ends, were found. None of the 5 ’RACE clones
contained the alternative 219 bp exon 2.
DNA preparations, primers and sequencing
Plasmid DNA used for sequencing or transfections was prepared by Thermo Scientific
GeneJet Plasmid Miniprep and Midiprep Kit (Thermo Fisher #K0502, #K0481), per
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the manufacturer’s instructions. DNA was quantified by an optical density at 260nm
using a NanoDrop Spectrophotometer (Thermo Scientific). Primers were purchased from
Integrated DNA Technologies, Inc. (IDT; Coralville, IA). DNA sequencing was performed
by ACGT, Inc. (Germantown, MD) or the University of Kentucky Genomics Core.
Transformation
Plasmid DNA was transformed into DH5α E. coli competent cells by incubating 3uL of
ligation reaction with 100uL of competent cells on ice for 30 minutes. Cells were heat
shocked for 45 seconds at 42oC, and incubated on ice for 2 minutes. 1mL of Luria
Bertani LB Broth (AMRESCO, #J106-500G) was added and the cells were shaken at
37oC for 1 hour. Cells were directly plated (100uL) and the remaining cells were pelleted
for one minute at 16,000 x g. LB media was decanted and the cells were resuspended in
the remaining liquid (50 uL). Cells were plated on LB Agar plates containing 50mg/mL of
Ampicillin, (LB/Amp) (Sigma) and incubated overnight at 37oC. For plasmid DNA
reactions ligated into pGEM-T Easy, 100 uL of ChromoMax TM IPTG/X-Gal Solution
(Fisher BioReagents # BP4200-1) was spread on LB/Amp plates and incubated for 1
hour at 37°C prior to plating the bacteria.
Plasmid Construction
Generation of asAFP promoter reporter plasmids
Various sized asAFP promoter fragments, between -2160 (#779), -830 (#874), -480
(#875), -320 (#876), -175 (#726), and -42 (#941) to +112 (#877) relative to transcription
start site (TSS), were generated from mouse genomic DNA (from M12 B cell line,
derived from a BALB/c mouse) using the Q5 high fidelity PCR amplification (NEB #
M0491S). The amplicons were purified, A-tailed with Taq Polymerase (NEB #M0267)
and cloned into pGEM-T Easy. The orientation of the insert within the plasmid was
determined by PCR using primers #387 and #861, for the SP6 orientation and primers
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#386 and #860 for the T7 orientation. The T7 oriented miniprep DNA plasmids were
sequenced (ACGT). Fragments were isolated by SpeI and Bglll restriction digest and
subcloned into the promoter-less pGL3-basic (no control elements) and pGL3-promoter
(promoter element only) luciferase reporter vectors (Promega) that had been linearized
by NheI and BgIII restriction digest. The asAFP -90 to +112 pGL3 basic promoter
reporter plasmid was generated by KpnI and BstXI restriction enzyme digest from the
asAFP -175 to +112 pGL3 basic reporter plasmid. The digested DNA was treated with
Klenow (NEB #MO210) to form blunt ends followed by T4 DNA ligation and
transformation into DH5α competent cells. Deletion of the putative Downstream
Promoter Element (DPE) promoter element was generated by PCR reactions with
primers #726/#942 and #941/#942, respectively, from mouse genomic DNA (from M12 B
cell line). Amplicons were A-tailed and cloned into pGEM-T Easy. The orientation of the
insert within the plasmid was determined by PCR primers #386 and #941 for Sp6
orientation and primers #387 and #942 for T7 orientation. T7 oriented clones were
sequenced and subcloned into pGL3 basic vector as described above.
Generation of asAFP RNA expression plasmids
To generate asAFP RNA expression plasmids, four segments that cover the entire
asAFP RNA transcript were amplified by high fidelity PCR amplification. To generate the
asAFP mid expression plasmid that contains an 1800bp fragment, primers #879 and
#836 were used and to make the asAFP 3’end expression plasmid that contains a
2000bp fragment, primers #835 and 870 were used in high fidelity PCR reactions from
mouse genomic DNA, since the genomic and cDNA were the same sequence. Two
asAFP 5’ alternatively spliced isoform expression plasmids were PCR amplified from
C3H/BL6 cDNA, primers #878 and #880-Xba. The asAFP 5-1 expression plasmid that
contains a 900 bp fragment, includes exon 219 and the asAFP 5-2 expression plasmid
that contains a 600bp fragment, skips exon 219. The amplicons were purified, A-tailed,
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cloned into pGEM-T Easy and sequenced. Fragments were excised by XbaI and XhoI
(asAFP mid), XhoI and EcoRI (asAFP 3’end) and XbaI and NheI (asAFP 5-1 and 5-2)
restriction digests and subcloned into pcDNA3.1(-) expression vector (Invitrogen V79020) that had been cut with appropriate restriction enzymes for directional cloning.
Primers were designed with restriction sites so that segments could be reassembled to
generate an asAFP full-length expression plasmid as diagrammed in Figure 5-1.
To generate pcDNA constructs that express AFP/asAFP overlapping cDNA
sequences, AFP exons 9-14 cDNA expression plasmid was generated from Zhx2∆hep
mouse liver RNA that was reverse transcribed by iScript cDNA synthesis and PCR
amplified using primers #328 and #761. The asAFP mid pGEM-T plasmid construct was
used to generate just exon 12by PCR amplification with primers #266 /#916. Amplicons
were purified, A-tailed, and cloned into pGEM-T Easy and sequenced. Fragments were
excised by EcoRI restriction digest, and subcloned into pcDNA. The pcDNA vector was
prepared for ligation by digestion with EcoRI to generate ends complementary to the
DNA insert. The digested vector was then treated with Antarctic Alkaline Phosphatase
(NEB, #M0289S) to remove the 5’-phosphate group from the exposed ends and ligated
to the prepared fragments. The orientation of the insert within the plasmid was
determined by PCR using primers #909 and #266 for (-) orientation and #909 and #267
for (+) orientation. Both orientations were isolated so that the sense strand could serve
as a control for the antisense strand.
A negative control expression plasmid that contained a 1147 bp fragment from
an intron within the IgM gene was generated by high fidelity PCR amplification using
primers #706 and #635. The amplicon was A-tailed, cloned into pGEM-T Easy and
sequenced. The fragment was excised by EcoRI restriction digest, and subcloned into
pcDNA treated with Antarctic Alkaline Phosphatase. The orientation of the insert within
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the plasmid was determined by PCR using primers #909 and #706 for (-) orientation and
#909 and #644 for (+) orientation.
Single primer mutagenesis was performed to generate expression plasmids that
contain AFP/asAFP overlapping intron sequences by removing the exon sequences
from the plasmids. The asAFP mid pGEM-T construct was used to delete exon 12
(Δe12) by PCR mutagenesis; reactions were performed per the protocol described by
Makarova, et al (Makarova et al., 2000). In this method, the single primer contains
sequences on either side of the desired deletion. Reactions included: 300 ng template
DNA, a single primer: #915, 200um dNTP, 1.25 U Q5 high fidelity polymerase and 5X
Q5 reaction buffer. The preliminary denaturation was at 95°C for 3 minutes, followed by
18 cycles of PCR cycles: 15 seconds of denaturation at 95°C. 1 minute of annealing at
56°C, and 12 minutes of extension at 68°C. The PCR reactions were digested with 1 uL
of DpnI endonuclease for 2 hours at 37°C to remove template DNA. Transformations
were performed using the following ratios of digest reaction to DH5α competent cells:
2uL /50 uL, 5ul/50ul, and 5uL/100Ul. The cells were combined, pelleted for one minute
at 16,000 x g and plated out on one LB/Amp Agar plate each. PCR was performed using
primers flanking the deletions to analyze 24 clones for exon 12 deletion (#872 /#759)
and 18 clones for exon 13 deletion (#815/ #432). The exon 12 and exon 13 deletion
efficiencies were 33% and 22% respectively. The fragment that contains the exon 12
deletion was excised by XbaI and XhoI restriction digest and cloned into pcDNA.
Miniprep plasmids for ADAR study
To distinguish RNA editing changes from DNA polymorphisms, various AFP/asAFP
overlapping regions were PCR amplified using primers #811 and #870 and #873 and
#836, respectively from total BL/6 Zhx2f/f wild-type liver cDNA and tail genomic DNA. A
2kb fragment that contains overlapping AFP/asAFP regions was PCR amplified (primers
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#714 and #759) from total and nuclear BL/6 Zhx2f/f wild-type liver cDNA. Amplicons
were purified, cloned into pGEM-T Easy and sequenced with universal primers SP6 and
T7. An asAFP-internal primer #836 was used to sequence the 2kb clones. A 782 bp
fragment that contains the AFP exon 9-14 cDNA that overlap with asAFP RNA was PCR
amplified using primers #328 /#761 from total BL/6 Zhx2 Alb-Cre expression (Zhx2∆hep)
liver cDNA. The amplicon was cloned into pGEM-T Easy, sequenced and aligned to AFP
mRNA and asAFP compiled RNA sequences for potential RNA editing (Geneious
software). Multiple clones were aligned to asAFP compiled RNA sequence for potential
RNA editing as diagrammed in Figure 5-7.
Cell Culture
Human Embryonic Kidney 293 (HEK 293), human hepatoma (HepG2 and Hep3B) and
C57/L (Leaden) derived mouse hepatoma (Hepa 1.6) mammalian cells were grown in
T25 flasks. Hepa 1.6, HEK 293, and Hep3B cells were maintained with Dulbecco’s
minimal eagle’s media (DMEM,) supplemented with 10% fetal bovine serum (FBS,
Gibco). HepG2 cells were supplemented with DMEM, 10% FBS, and 0.1 % Insulin. All
cells were maintained in an incubator at 37°C and 5% CO2.
Transient DNA Transfections
For asAFP promoter studies, HEK 293 and Hep3B cells were seeded 2.0 x 105 and
Hepa 1.6 cells were seeded 1.0 × 105 cells/well in 24-well plates supplemented with 500
uL of the appropriate media for 24 hours prior to transfection. The next day, serum free
DMEM media (50 uL) was diluted with TK/Renilla (10 ng) and reporter plasmid DNA
(500ng). Turbofect reagent (Thermo Scientific, #R0532) was added to the diluted DNA,
vortexed, and incubated for 20 minutes at room temperature. The complex was added to
cells in a dropwise manner, gently swirled to mix and incubated for 48 hours. After 48hour incubation, cells were harvested for Dual Luciferase Reporter assay.
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For transient transfections with asAFP expression vectors, Hepa 1.6 cells were
seeded 2.0 x 105 cells/well in 6 well plates supplemented with 2mL of the appropriate
media for 24 hours prior to transfection. The next day, serum-free DMEM (200 uL)
media was diluted with 5ug of expression plasmid DNA. Turbofect reagent (10uL) was
added to the diluted DNA and added to cells as previously described. After 48-hour
incubation, cells were harvested for total RNA isolation.
Dual Luciferase Reporter Assay System
Cells were harvested 48 hrs post transfection and washed with sterile 1X phosphate
buffered saline (PBS), followed by lysis with 1x Passive Lysis Buffer (100 uL) for 15
minutes, while rocking. Cell lysates (20uL) were placed in duplicate wells of 96-well
luciferase plates (CoStar). Analysis was performed using the GloMax Explorer
(Promega). Both dual luciferase substrates (Promega) were each injected (100uL) into
the designated wells. Luciferase values were corrected relative to Renilla values. The
pGL3 negative control luciferase values were set to 1 and asAFP promoter luciferase
values were normalized to these control values. The average and standard deviation are
shown from at least three independent analyses.
RNA Extraction, cDNA Synthesis, and RT-qPCR
Total RNA from 2.0 × 105 transiently transfected Hepa 1.6 cells was extracted with
0.5mL RNAzol RT (Molecular Research Center, Inc., Cincinnati, Ohio). Total RNA from
mouse tissues were obtained by homogenization of about 50 mg in 1mL RNAzol RT, per
manufacturer’s protocol. RNA was eluted with 50 µl of Nuclease -free water and
quantified by OD measurement. Some RNA preparations were DNase treated using the
Turbo DNA-free kit (Ambion #AM1907) to remove contaminating genomic DNA or
residual plasmid DNA. Briefly, total RNA (5ug) was incubated with 10x Turbo DNase
buffer and Turbo DNase enzyme (1uL). Half of the Turbo DNase enzyme was initially
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added to the reaction and incubated for 30 minutes at 37°C and the remaining enzyme
was added incubated for 30 minutes at 37°C. DNase Inactivation reagent (2uL) and
Nuclease-free water (3uL) was added to the reaction and incubated for 5 minutes at
room temperature, mixing occasionally. The reaction was centrifuged at 10,000 x g for
1.5 minutes and the supernatant RNA was transferred to a clean 0.5mL Eppendorf tube.
cDNA was synthesized from 1 ug of RNA using the iScript cDNA Synthesis Kit (BioRad
#170-8891) per manufacturer’s protocol. Quantitative Real-Time PCR (qPCR) reactions
using SYBR Green PCR Supermix (BioRad #172-5275) were performed using the
CFX96 Touch Real-Time PCR Detection System and analyzed using the CFX Manager
software (BioRad). To measure detectable endogenous AFP mRNA levels from Hepa
1.6 cells by RT-qPCR, 2 ul of undiluted RT input was required and 1 ul was used for all
other RNAs. qPCR Ct values were normalized to the ribosomal protein L30 and were
calculated using the ∆∆Ct method.
Flow Cytometry
Hepa 1.6 cells were co-transfected with 4.5 ug of asAFP RNA plasmids and 0.5 ug of a
plasmid expressing GFP as a reporter. Reporter expression was determined 48 hr after
transfection by flow cytometry. To prepare cells for flow analysis, cells were trypsinized
for 3 minutes, resuspended in sterile 1X PBS, and centrifuged at 1000 x g for minutes.
Cells were washed once with sterile 1X PBS, filtered through a 0.2um sterile filter and
resuspended in Basic Sorting Buffer (1X PBS, 0.5 M EDTA, 0.5M HEPES (pH 7.0)), and
1X Fetal Bovine Serum. Cells were analyzed Becton-Dickinson FACSCalibur flow
cytometer and analyzed by the BD CellQuest™ Pro software (San Jose, CA). Total RNA
isolated from unsorted, sorted GFP positive, and GFP negative cells was reverse
transcribed and changes in endogenous AFP was measured by RT-qPCR.
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Bioinformatic Tools
The UCSC Genome Browser on the Mouse Dec. 2011 (GRCm38/mm10)
(http://genome.ucsc.edu) was used to analyze the evolutionary conservation of mouse
asAFP RNA with other mammalian species. The NCBI Open Reading Frame Finder
(ORF finder) (https://www.ncbi.nlm.nih.gov/orffinder) was used to search for asAFP RNA
predicted ORFs. The Coding Potential Assessment Tool (CPAT)
(http://lilab.research.bcm.edu/cpat/index.php) was used to assess the coding potential of
AFP mRNA and asAFP RNA. The Jaspar database (jaspar.genereg.net/ ) was used to
identify candidate transcription factors that could bind to asAFP promoter sequences.
The ElemeNT navigation tool (http://lifefaculty.biu.ac.il/gershontamar/index.php/resources) was used to identify putative asAFP core promoter
elements. The asAFP -175 to +106, relative to TSS, was used as the input sequence.
Geneious was used for the alignment of asAFP cDNA clones with asAFP RNA and AFP
mRNA consensus templates.
Statistical Analysis
All values within a group were averaged and plotted as mean +/- standard deviation. pvalues were calculated between two groups using student’s t-test and between three or
more groups by ANOVA followed by Tukey’s test. A p-value < 0.05 was considered
significant. Data was graphed and analyzed using GraphPad Prism 6 software.

32

Table 2.1. Plasmid constructs used for asAFP promoter study
plasmid
pGEM-T Easy
vector
pGL3- Basic
pGL3- Promoter
asAFP -2160 to
+112
asAFP -830 to
+112
asAFP -480 to
+112
asAFP -320 to
+112
asAFP -175 to
+112
asAFP -175 to +29
asAFP -42 to +112
asAFP -42 to +29
Tk/Renilla
HA-Zhx2
Mup20 promoter

Description
cloning vector for PCR products (Promega)
empty vector driving luciferase (Promega)
SV40 promoter upstream of the luciferase (Promega)
2-kb fragment from (M12, B cell line) mouse genomic DNA was
inserted into Spe1-NheI/BglII pGL3 basic vector
943 bp fragment from M12 mouse genomic DNA was inserted
into Spe1-NheI/BglII pGL3 basic and pGL3 promoter vector,
respectivley
594bp fragment from M12 mouse genomic DNA was inserted
into Spe1-NheI/BglII pGL3 basic vector
430 bp fragment from M12 mouse genomic DNA was inserted
into Spe1-NheI/BglII pGL3 basic vector
256 bp fragment from M12 mouse genomic DNA was inserted
into Spe1-NheI/BglII pGL3 basic vector
204 bp fragment from M12 mouse genomic DNA was inserted
into Spe1-NheI/BglII pGL3 basic vector
154 bp fragment from M12 mouse genomic DNA was inserted
into Spe1-NheI/BglII pGL3 basic vector
71 bp fragment from M12 mouse genomic DNA was inserted
into Spe1-NheI/BglII pGL3 basic vector
HSV-thymidine kinase promoter Renilla luciferase control
reporter (Promega)
full-length Zhx2 with 5' HA epitope inserted into pcDNA 3.1(-)
(Spear/Peterson lab)
∼1.4-kb fragment inserted into the pGL4.14[luc2/Hygro]
luciferase vector (Promega) (Jiang, Creasy et al. 2017)
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Table 2.2. Plasmid constructs used for asAFP functional study
plasmid
pcDNA 3.1(-)
asAFP 5-1 pcDNA
asAFP 5-2 pcDNA
asAFP mid pcDNA
asAFP 3' pcDNA
asAFP 3+mid
pcDNA
e12 (-) pcDNA
delta e12 pcDNA
AFP e9-14 (+)
pcDNA
IgM pcDNA

Description
empty expression vector (Invitrogen)
900 bp fragment inserted 3'-5' orientation NheI and XbaI site of
pcDNA 3.1(-)
600 bp fragment inserted 3'-5' orientation NheI and XbaI site of
pcDNA 3.1(-)
1800 bp fragment inserted 3'-5' orientation between XbaI and
XhoI site of pcDNA3.1 (-)
3-kb fragment inserted 3'-5' orientation between XhoI and EcoRI
sites of pcDNA3.1(-)
3.8-kb fragment inserted 3'-5' orientation between XbaI and
EcoRI site of pcDNA3.1(-)
224 bp fragment inserted 3'-5' orientation in pcDNA 3.1 (-)
EcoR1 site
1576 bp fragment inserted 3'-5' orientation in pcDNA 3.1 (-)
EcoR1 site
782 bp fragment inserted 5'-3' orientation in pcDNA 3.1 (-)
EcoR1 site
1147 bp fragment inserted 3'-5' orientation in pcDNA 3.1 (-)
EcoR1 site

Table 2.3. Oligos used for 5’RACE
lab oligo
725
kit

760
kit
396
824
726
831
776

oligo name
i13-F (used for RT)
oligo (dT)-anchor
primer 1 (provided in
kit)
AFPi13/e14-Fq
anchor primer 2
(provided in kit)
Afp 3'-F
AFPds6.7-F
AFP_AS-F
Ex219-R
AFPds6.9-F

sequence
CTC CTG ACC TCA CTT AAG AGC GAG
GAC CAC GCG TAT CGA TGT CGA CTT TTT TTT
TTT TTT TTV (V = A, C, or T)
TAA GAG CGA GCA CAC TGA CA
GAC CAC GCG TAT CGA TGT CGA C
TTG ATT TCC AAA ACT CGT GAG C
CTC ATC TCT TCA TAC CGC TTT
CCG CTA CAG AGA AAG TGG AAT GA
GTT CTC CTT GCT AGT GGG TAT CA
CCC AAA AGC TGC ATC ACC AC
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Table 2.4. Oligos used for asAFP promoter study
386
387
726
779
860
861
874
875
876
877
941
942

pGEMU
pGEML
AFP_AS-F
AFP ds8.8-R
AS5’Ex-R2
AS5’Ex-F2
asAFP-P1
asAFP-P2
asAFP-P3
850-Bgl
asP-42-F
asP-42-R

CACTATAGGGCGAATTGG
CAAGCTATGCATCCAACG
CCG CTA CAG AGA AAG TGG AAT GA
TTC GAG ATG CTC ACA AGG GT
GTG AGA CCT TGT TCC TGT CTC C
GGC AAC CAT ACA ACC AGC AAA G
GGA TGC AGG TGG ACC TTA AA
CCT CTC AGG CCC ATT GAT ATG
AAC GAT AGT AGG CTG ATG GTA ATG
AGA TCT GCG GTA TGA AGA GAT GAG AAG G
ACT AGT CAT GCC CTG TAA GCC TAG AC
AGA TCTCAAGGTCTCACCCCATCGA

Table 2.5. Oligos used for asAFP functional study
266

AFPE12S

CCA GGC CGA CAT TTT CAT TGG ACA

266
267
328
386
387
432
635
706
761
835
836
870
872
878
879
880

AFPE12S
AFPE12A
E9E10-F
pGEMU
pGEML
nest 12-13 BF
Igμmbr
8303 fw
AFPi13/e14-Rq
i11-R1
i11-F2
i8-F3
i11-F
860-Nhe
1012-Xba-T
1012-Xba-B

909
915

3.1U
e12del

916

E12-rev

CCA GGC CGA CAT TTT CAT TGG ACA
TGA GCT TGG CAC AGA TCC TTG TGG A
CTT CAT GAA TAC TCA AGA ACT CAC C
CACTATAGGGCGAATTGG
CAAGCTATGCATCCAACG
TTC TCC CAG TTT TCT TCA CCC CAG
TTC TCA AAG CCT TCC TCC TCA GCA
TGG ACA CTT ACA AAC GCC TTC AGA G
GCC CAA AGC ATC ACG AGT TT
CCT CAA CAA GAC CAG GAC AT
CCA AGC AAA GTA CAG GAG TAA GA
CTG AGC CTG GCT TAT TCA CTT A
GGA CCG GAG TTT GGA CCT T
GCT AGC GTG AGA CCT TGT TCC TGT CTC C
GTG CTC TCT GTC TAG ATT ACT ACA TTA TCC
GGA TAA TGT AGT AAT CTA GAC AGA GAG
CAC
TTAATACGACTCACTATAGGGAGACC
TTT TGT CTG CCT GCT TCC TTC GTA AGA CAT
TGT TAT TTT GAG CTG AGA C
ACT CTT GTT TCA TGG TCT GTA GGG
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Table 2.6. Oligos used for PCR and sequencing in ADAR study
328
386
387
714
759
761
811
836
836
870
873
SP6
T7

E9E10-F
pGEML
pGEMU
i10-F2
AFPe/i12-Rq
AFPi13/e14-Rq
AFPi9-R
i11-F2
i11-F2 (sequencing)
i8-F3
i11-R
universal primer
universal primer

CTT CAT GAA TAC TCA AGA ACT CAC C
CACTATAGGGCGAATTGG
CAAGCTATGCATCCAACG
GGT TCC AAC ACC CAA AGT ACA CGG T
AGG GCA GCA ATG TTC TAC TGA
GCC CAA AGC ATC ACG AGT TT
CTC TGT GGA GTG CAG TTC TT
CCA AGC AAA GTA CAG GAG TAA GA
CCA AGC AAA GTA CAG GAG TAA GA
CTG AGC CTG GCT TAT TCA CTT A
CAG ATG AGA GTT GGG TAC CTG TG
GAT TTA GGT GAC ACT ATA G
TAA TAC GAC TCA CTA TAG GG

Table 2.7 Oligos used for RT-qPCR
137
138
267
324
325
432
752
753
825
833
909
910
1283
1284

L30F
L30R
AFPE12A
E2E3-F
E2E3-R
nest 12-13 BF
mAlbmlpF
mAlbmlpR
AS-RACE-2
e9-R
3.1U
3.1L
AFM-138
AFM-158

ATG GTG GCC GCA AAG AAG ACG AA
CCT CAA AGC TGG ACA GTT GTT GGC A
TGA GCT TGG CAC AGA TCC TTG TGG A
TCC ACG TTA GAT TCC TCC CAG TGC G
TGT TCA CTT CCT CCT CGG TGG CTT C
TTC TCC CAG TTT TCT TCA CCC CAG
TGA AAT GCG AGG TAA GTA TGG T
AGG TTA CCC ACT TCA TTT TGC C
GCA ACC ATA CAA CCA GCA AAG A
AAT GAC TGA GAC AGG AAG GTT G
TTAATACGACTCACTATAGGGAGACC
TAG AAG GCA CAG TCG AGG CTG ATC AG
GGA TCC AGA AAT TTG CAC CAG GAC CGA A
GGA TCC CCT AGT TAA TAA TTA CCT AGA
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CHAPTER III
IDENTIFICATION AND CHARACTERIZATION OF NOVEL asAFP RNA
TRANSCRIPTS IN MOUSE LIVER
Recent advances in high throughput RNA-sequencing (RNA-seq) have led to the
discovery of thousands of unannotated noncoding RNA transcripts in the mammalian
genome. Long noncoding RNAs (lncRNAs) are a heterogeneous group of RNA
molecules that are > 200 nt in length and share similar features of mRNAs (Quan et al.,
2015; Yan and Wang, 2012). Many identified lncRNAs are transcribed by RNA
polymerase II (RNA pol II) and are polyadenylated, but lack significant open-reading
frames. They can be identified through bioinformatics prediction or a high-throughput
analysis such as microarrays and transcriptome analysis (Yan and Wang, 2012). They
are generally poorly conserved, tissue-specific transcripts. lncRNAs can function in the
nucleus or cytoplasm to regulate gene expression at the transcriptional or posttranscriptional level in a positive (concordant) or negative (discordant) manner. The
expression of some lncRNAs are correlated with expression of neighboring genes, while
others have inverse expression patterns during development and disease (Zhang et al.,
2014). A number of well-characterized lncRNAs have provided clues about the biology of
these transcripts and their proposed mechanisms, but a key question for each identified
transcript is whether it has a biological function.
Our research has focused on the role of developmentally regulated protein
coding genes including alpha-fetoprotein (AFP). AFP was the first HCC-associated
oncofetal protein and is the most commonly used serum biomarker for liver damage and
Hepatocellular Carcinoma (HCC). AFP is expressed abundantly in fetal liver,
dramatically repressed at birth, and reactivated in liver damage and cancer. More than
forty years ago, BALB/cJ mice were shown to express 20-fold higher AFP serum and
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adult liver mRNA levels compared to 27 other inbred mouse strains (Belayew and
Tilghman, 1982; Olsson et al., 1977). The locus controlling this post-natal persistence of
AFP levels in BALB/cJ mice was named raf (regulator of AFP), later named Afr1 (Alphafetoprotein regulator 1) (Belayew and Tilghman, 1982).
Our lab identified Zinc-fingers and homeoboxes 2 (Zhx2) as the gene that is
responsible for continued expression of AFP and H19, another Afr1-regulated gene, in
adult BALB/cJ liver (Perincheri et al., 2005). The Afr1 allele of Zhx2 in BALB/cJ mice
contains an ETnIIα mouse endogenous retroviral element in intron 1 that drastically
reduces Zhx2 expression in this strain. Low levels of Zhx2 in BALB/cJ mice correlates
with increased levels of AFP and other developmentally regulated target genes including
H19, Glypican 3 (Gpc3), and Lipoprotein lipase. However, it is not well known which
genes are direct vs indirect targets of Zhx2 (Gargalovic et al., 2010; Morford et al., 2007;
Pachnis et al., 1984).
Transgenic mouse studies showed that Zhx2 acts through the 250 bp AFP
promoter and that a Zhx2 transgene driven by a liver specific promoter restored normal
AFP silencing in adult BALB/cJ liver (Perincheri et al., 2005; Peyton et al., 2000a).
However, transcriptional rates on the AFP and H19 genes, measured by nuclear run-on
assays, were the same in the presence or absence of Zhx2 expression, indicating that
Zhx2 may act at the post-transcriptional level (Morford, unpublished; Vacher et al.,
1992). Therefore, the Peterson lab explored splicing across the AFP gene as possible
post-transcriptional step that could be affected by Zhx2 regulation. In the presence of
Zhx2, low levels of mature mRNA were detected, as expected, however, elevated levels
of unspliced RNA from the AFP exon 10/11 region was also detected and this was not
expected (Lilia Turcios, unpublished). To further characterize the “unspliced RNA”,
strand-specific reverse transcriptase (RT) primers were used, followed by PCR. The
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strand-specific RT primers showed that the “unspliced” RNAs were actually transcribed
from the antisense DNA strand. Thus, these RNAs are now named antisense AFP
(asAFP). To identify the ends of asAFP RNA, multiple overlapping RT-PCR reactions
were performed, starting from the originally identified exon 10/11 region and extending in
both the 5’ and 3’ directions. When a PCR product was not detected, this region was
used to anchor 3’ and 5’ Rapid Amplification of cDNA ends (RACE) reactions. One
product was smaller than predicted and identified a 338 bp intron in the asAFP RNA.
The 3’ RACE results identified a major 3’ end in the region of AFP intron 8 (Qiu et al, in
prep).
RESULTS
Identification of asAFP 5’ end
To identify the 5’ end of the asAFP RNA, I performed 5’ RACE on liver RNA from
BALB/cJ mice that express a liver-specific Zhx2 transgene. These transgenic mice
express similar levels of Zhx2 as BALB/c mice with wild type Zhx2 expression and
postnatal repression of AFP. For these experiments, I used a gene-specific RT primer
and two nested gene-specific PCR primers located within the confirmed region of asAFP
but where standard PCR reactions using additional upstream primers did not detect
products (Figure 3-1A). The final products from the second nested PCR reaction were
cloned and sequenced (Figure 3-1B). I aligned various sized RACE clones to the UCSC
genome database (NCBI37/mm9). Only one RACE clone mapped to a region ~6.8 kb
downstream of the AFP gene in the opposite orientation. The 5’ RACE identified a 123
bp asAFP exon 1 (123bp) (Figure 3-1C). The remaining 5’ RACE clones were either
found on a different locus or were from repetitive elements, suggesting artifacts
produced by spurious priming in the PCR. Additional RT-PCR reactions, using a primer
in this new 5’ exon and primers within the previously identified part of asAFP, identified a
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219bp asAFP exon 2 that is spliced into some of the RNAs. This analysis also identified
asAFP exon 3 as an alternative exon (Qiu et al, in prep). Based on these analyses
asAFP is a 5kb transcript that contains 4 exons and 3 major spliced isoforms that
partially overlaps the 3’ half of the AFP gene (Figure 3-2).
asAFP is a noncoding RNA
To investigate asAFP RNA coding potential, I first searched for open reading
frames (ORFs) using NCBI Open Reading Frame Finder (ORF finder). This tool
identified multiple predicted small ORFs of 98 amino acids or smaller (Figure 3-3A).
BLAST analysis of the longer putative ORFs failed to reveal any known functional
domains or homology to known proteins. To determine coding potential, I used the
Coding Potential Assessment tool (CPAT) and analyzed asAFP RNA along with the AFP
and albumin mRNAs as known coding genes and H19 RNA as a known non-coding
gene. The CPAT tool predicts coding potential based on ORF features to distinguish
between coding and noncoding RNAs. The protein coding genes AFP and albumin
mRNAs were scored as coding RNAs with coding probabilities of 0.99. Like H19 RNA,
asAFP RNA was scored as a noncoding RNA with coding probabilities of 0.30 and 0.04
respectively, suggesting that it is highly unlikely that any of the ORFs in asAFP encode
proteins (Figure 3-3C).
To analyze the evolutionary conservation of mouse asAFP RNA with other
mammalian species, I utilized UCSC Genome Browser on the Mouse Dec. 2011
(GRCm38/mm10) Assembly (Kent et al., 2002). I performed BLAT alignment of the
asAFP genomic sequence that mapped to the mouse AFP genome. The multiple
sequence alignment track (Multiz) and the Placental Mammal Basewise Conservation by
PhyloP tracks were selected to display analysis of evolutionary conservation. My
analysis revealed that the asAFP primary sequence is poorly conserved between all
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species except for rat (Figure 3-4). Altogether, my results demonstrate that mouse
asAFP is a novel, poorly conserved noncoding RNA.
AFP and asAFP are co-expressed in adult mouse tissues
I analyzed AFP and asAFP transcript levels, by RT-qPCR using total RNA
isolated from a panel of tissues from adult BL/6 mice with a hepatocyte-specific deletion
of Zhx2 (Zhx2∆hep), including liver, spleen, small intestine, kidney, heart and lung. Both
transcripts were predominantly expressed in the liver and to a lesser extent in the small
intestine (Figure 3-5A). We also analyzed levels of asAFP and AFP mRNA in liver RNA
from multiple sets of adult littermate BALB/cJ mice with or without a liver-specific Zhx2
transgene. These mice express normal or low Zhx2 levels, respectively. As expected,
AFP mRNA levels were lower in the presence of Zhx2 and higher in the absence of
Zhx2. However, the asAFP RNA levels were higher in the presence of Zhx2 and lower in
the absence of Zhx2 (Figure 3.5B). Taken together, we demonstrate AFP and asAFP
transcripts are co-expressed in mouse liver and the expression differs with the Zhx2
status of the mice, suggesting there may be a regulatory connection.
asAFP RNA levels are not altered in liver tumors
Previous studies have shown the expression of several antisense RNAs are
dysregulated in HCC (Qin et al., 2016; Yuan et al., 2014; Zhu et al., 2016). I explored the
expression profiles of hepatic AFP mRNA, Zhx2 mRNA and asAFP RNA levels by RTqPCR using total RNA isolated from mouse model of HCC, as described (Creasy et al.,
2016). Consistent with the findings of Creasy, et al., I observed increased hepatic AFP
mRNA levels in tumors compared to normal livers. However, I observed no differences
in Zhx2 mRNA or asAFP RNA expression between normal liver or liver tumors (Figure 36). These findings indicate that asAFP RNA expression is not altered in tumors and
suggests that it may not be involved in regulating AFP mRNA during liver cancer.
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Discussion
Alpha fetoprotein (AFP) was the first identified HCC-associated oncofetal protein
and is still the most commonly used serum biomarker for HCC (Abelev, 1971; Behne
and Copur, 2012). AFP is a member of the serum albumin gene family and is highly
expressed in the fetal liver and yolk sac; serum AFP levels decrease dramatically during
the first several weeks after birth due to the significant repression of AFP mRNA (~105fold) in the liver (Belayew and Tilghman, 1982; Peterson et al., 2011). Postnatal AFP
mRNA levels remain at low basal levels in normal adult liver, but AFP expression can be
reactivated during liver regeneration and in HCC (Abelev, 1971). Our laboratory has
been studying mouse liver gene regulation, focused on AFP, to better understand
mechanisms by which changes in gene expression contribute to liver development,
homeostasis and disease.
In this study, we identified novel antisense transcripts that are transcribed on the
opposite strand of the AFP gene, named asAFP. We performed 5’ and 3’ RACE to
characterize the genomic structure of asAFP. asAFP are ~5kb transcripts that partially
overlap the 3’ half of AFP mRNA. asAFP contains 4 exons and 3 major spliced isoforms
with similar abundance. In addition to the characterization data shown here, others in the
lab have shown RNA-seq data from adult mouse liver confirmed the 5’ end, aligned to
our experimentally validated splice junctions and supported the quantitative analysis of
the relative isoform abundance. This data also identified additional asAFP RNAs that
splice to locations further downstream from the major asAFP 3’ end. The subcellular
location of asAFP RNA was assessed from cytoplasmic and nuclear RNA extracted from
adult BALB/cJ mice with or without the Zhx2 transgene. asAFP RNA accumulated to
significantly higher levels in the cytoplasm compared to the nucleus. The difference in
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AFP mRNA accumulation in the presence or absence of Zhx2 was observed in the
cytoplasmic RNA, but not in the nuclear RNA, suggesting that AFP mRNA regulation
occurs at a step after nuclear mRNA processing (Qiu et al, in prep). In addition,
cytoplasmic asAFP RNA and AFP mRNA abundance were in a similar range, but
correlated with the Zhx2 status of the mice (Qiu et al, in prep). AFP mRNA levels were
lower in the presence of Zhx2, whereas asAFP RNA levels were higher in the presence
of Zhx2, suggesting a regulatory connection between Zhx2 and asAFP.
LncRNAs are considered noncoding because they lack open reading frames that
are >100 amino acids and any ORFs present have no evolutionary conservation or
homology to known protein domains (Zhang et al., 2014). I identified several predicted
ORFs in asAFP RNA that are 98 aa or smaller but coding potential analysis suggests
that asAFP is a noncoding RNA. Moreover, further characterization of asAFP seqeunces
showed no evidence of evolutionary conservation with human. In addition, we
demonstrated AFP and asAFP are co-expressed in adult mouse tissues and their levels
of abundance differ with the status of Zhx2 in adult mouse liver. Our developmental
studies revealed that both asAFP RNA and Zhx2 mRNA are expressed at low levels in
the fetal liver and increase gradually after birth while AFP expression decreases (Qiu et
al, in prep). To determine whether asAFP plays a role in regulating AFP mRNA
reactivation in tumors, I measured AFP, asAFP, and Zhx2 expression in tumor and
nontumor samples from a mouse model of HCC. Consistent with previous findings, AFP
expression was increased in tumors. However, asAFP and Zhx2 mRNA levels were not
altered. This suggests that asAFP is not directly involved in the mechanism by which
AFP is reactivated in tumors. While Zhx2 mRNA levels do not change in liver tumors,
ZHX2 protein levels have been shown to be frequently localized to the cytoplasm in
human tumors, compared to its nuclear location in normal cells (Shen et al., 2008).
Altogether, we have identified novel unannotated asAFP transcripts that partially overlap
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the AFP gene. Our observation that both AFP and asAFP are co-expressed in mouse
liver and are inversely correlated depending on Zhx2, suggests a regulatory connection
between these transcripts and Zhx2 during liver development. Therefore, it is important
to understand asAFP transcriptional regulation and its potential biological function.
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Figure 3-1. asAFP 5′ RACE strategy. Map of the AFP gene from exon 8 to about 7 kb
downstream of exon 15. Above the line are the AFP exons (open boxes), with the exon
and intron sizes shown. Below the line are shown the exons (grey boxes) and introns
identified for the antisense transcripts, with their sizes shown. The transcriptional
orientation of the two transcription units is shown above the map. (A) Schematic
representation of asAFP 5’ RACE strategy. The primers used for the 5’ RACE are shown
directly below the diagram. i13 was used for RT and e13 and e14 were used for the PCR
reactions. (B) Gel from the 5’ RACE experiment. Multiple bands were cloned and
sequenced; the arrow identified by (5’ RACE) is gene-specific and identified an asAFP
exon located about 6.8 kb downstream from AFP exon 15. The other bands in the gel
were from repetitive elements. (C) Visualization of asAFP 5’ RACE clone in UCSC
Genome Browser, mm9 assembly. asAFP is transcribed beginning ~6.8 kb downstream
from AFP gene and ~2kb upstream the adjacent, Afamin (Afm) gene.
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Figure 3-2. Complete view of characterized asAFP transcripts. Map of the AFP gene
from intron 6 to about 7 kb downstream of exon 15 (map not drawn to scale). Above the
line are the AFP exons (open boxes), with the exon and intron sizes shown. Below the
line are shown the asAFP exons (grey boxes) and introns identified for the antisense
transcripts, with their sizes shown; the dark grey boxes are exons identified by RNA-seq.
The transcriptional orientation of the two transcription units is shown above the map. The
alternative splicing reactions identified for the asAFP transcripts are identified by the
angled lines connecting alternative exons. RNA-seq data from adult mouse liver
confirmed the asAFP exons 1-4 and identified two additional alternative exons located
downstream from the major asAFP 3’ end (dark grey boxes) which were detected by RTPCR and RT-qPCR and found to be low abundance RNAs (dotted lines). RNA-seq data
received from Joe Locker (University of Pittsburgh) and analysis performed by Jinze Liu
(University of Kentucky).
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Figure 3-3. asAFP is a noncoding RNA. (A) Schematic representation of asAFP open
reading frames (ORFs) adapted from https://www.ncbi.nlm.nih.gov/orffinder, oriented 5’3’ relative to the asAFP RNA. ORFs are delimited by AUG start codons and UAG, UAA
or UGA termination codons. The ORFs within each reading frame are color coded in
boxes with arrows and the numbers indicate the size, in amino acids (aa). The ORF
cutoff was set at > 30 aa. The two largest ORFs are 90 aa (5’) and 98 aa (3’). (B) A
screenshot of the Coding Potential Assessment Tool (CPAT) output when the AFP
mRNA and asAFP RNA sequences were submitted to
http://lilab.research.bcm.edu/cpat/index.php. Based on the coding probability (> 0.364
suggests coding sequence), this tool predicts that AFP mRNA clearly codes for a protein
while asAFP RNA is highly likely to be noncoding.
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Figure 3-4. Sequence conservation analysis of asAFP (chromosome 5, bp 90505000–
90510000) in the UCSC genome browser (UCSC Genome Browser on the Mouse Dec.
2011 (GRCm38/mm10) Assembly (http://genome.ucsc.edu.) (Kent, Sugnet et al. 2002).
The RefSeq AFP transcript exon 8-15 (below) and asAFP cDNA (above). MultiZ Align,
multiple sequence alignment of 30 vertebrates and Mammalian conservation tracks. The
most magnified view at the bottom depicts species alignment with primates (green) and
placental mammals (blue).
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Figure 3-5. AFP mRNA and asAFP RNA are co-expressed in mouse tissues. (A)
Expression of AFP mRNA and asAFP RNA were measured from BL/6 Zhx2∆hep mouse
tissues including small intestine, liver, testes, heart, muscle, and kidney, by RT-qPCR.
Data shown represents one mouse. (B) RT-qPCR of total RNA of adult BALB/cJ
littermates that express a liver-specific Zhx2 transgene (Zhx2+Tg) or without the
transgene (Zhx2-Tg); data from a single pair of animals but is representative of multiple
animals. Ribosomal protein L30 was used as an internal control.
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Figure 3-6. asAFP RNA levels ares not altered in tumors. Male C3H-B6 mice were
injected with phosphate buffer saline, control (PBS, n=4) or diethylnitrosamine (DEN,
n=8) to initiate liver tumor development in a mouse model of HCC. The total liver RNA
isolated from normal liver (PBS-injected) or HCC tumors (DEN-treated) mice was
analyzed by RT-qPCR for expression of AFP, asAFP, and Zhx2. AFP mRNA levels are
higher in tumors, but asAFP and Zhx2 mRNA levels are not altered. Expression was
calculated relative to the ribosomal protein L30 internal control and the expression in
normal liver tissue set to 1. Samples were provided by Kate Townsend Creasy.

Copyright © Maria S. Dixon 2017
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CHAPTER IV
TRANSCRIPTIONAL REGULATION OF asAFP

The discovery of lncRNAs has gained extensive attention for their potential role
in regulating gene expression. Like protein coding genes, lncRNAs display chromatin
features associated with active transcription, such as trimethylation of histone H3 lysine
4 trimethylation (H3K4me3) at their promoters and histone H3 lysine 36 trimethylation
(H3K36me3) throughout their gene body (Lin et al., 2015). The transcriptional activity of
lncRNA’s can be regulated by standard promoters or enhancers to influence gene
expression. Therefore, it is important to identify the transcriptional regulators that
promote the expression of lncRNAs.
Eukaryotic gene expression is regulated by the interaction between the basal
transcriptional machinery and the core promoter. The basal transcriptional machinery is
composed of RNA pol II and basal transcription factors that direct accurate initiation of
transcription. The core promoter is composed of diverse cis-acting regulatory elements
that function independently or together to regulate transcriptional activity, such as the
TATA box, an initiator (Inr), downstream promoter element (DPE), and motif ten element
(MTE) (Figure 1-3) (Butler and Kadonaga, 2002). Only 20% of eukaryotic promoters
contain a TATA box that directs the preinitiation complex to the transcriptional start site
(TSS) within the Inr element. Transcription from TATA-less promoters also usually
initiate within the Inr in conjunction with other core promoter elements. The Inr
encompasses the TSS; the A within this sequence is designated as the +1 position.
Transcription does not always begin at the A, but the Inr A+1 is the position that is used
to count the spacing to other promoter elements, including the DPE and MTE. The
function of these elements depends on strict distances from the Inr. In summary, the
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core promoter is structurally and functionally diverse and multiple combinations of
promoter elements can initiate transcription.
Enhancers have been shown to generate non-coding RNAs (eRNAs), many of
which are short and unstable. However, some of these eRNAs can also be spliced,
polyadenylated and stable (Kim et al., 2010; Lin et al., 2015; Orom and Shiekhattar,
2011a). eRNA levels often correlate with mRNA expression levels at nearby genes (Kim
et al., 2010). While there are a few examples of eRNAs that contribute to enhancer
function, possibly by looping the DNA sequences between enhancers to their target
promoters or by regulating chromatin modifications that keeps enhancers and promoters
in their active states, the vast majority have not been studied. Some eRNAs also may
not play a direct role beyond marking the enhancer DNA as an open chromosomal
region (Orom and Shiekhattar, 2011a).
We have characterized novel asAFP transcripts that partially overlap the 3’ half
of the mouse AFP gene. We found that AFP mRNA and asAFP RNA are co-expressed
in mouse liver and their abundance is inversely correlated in mouse strains that contain
wild-type and low levels of Zhx2. To test the hypothesis that Zhx2 regulates the
expression of asAFP RNA, which then contributes to AFP mRNA regulation, requires
that we characterize the asAFP transcriptional control elements.

Results
Identification of cis-acting sequences required for asAFP transcriptional activity
To identify the genomic regions that promote asAFP transcription, we began with
publicly available ENCODE data from the UCSC Genome Browser
(http://genome.ucsc.edu/) (Raney et al., 2014). The mouse 8-week liver ChIP-seq data
of chromatin modifications associated with active promoters and enhancers was
visualized in the region of the AFP, asAFP, and Afamin (Afm) genomic region. The
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regulatory elements that drive AFP expression are contained within a 7.6 kb region
upstream of the AFP transcription start site and include the promoter and three enhancer
elements. The three enhancers: E1, E2, and E3 are positioned about -2.5, -5.0 and -6.5
kb, respectively, and are each about 200-300 bp in length (Godbout et al., 1988). E1 and
E2 are highly similar suggesting they arose from a duplication event; moreover, E1 is
present in rodent but it is absent in several other species analyzed (Long et al., 2004).
Transgenic studies showed that all three enhancers are active in both fetal and adult
mouse livers (Ramesh et al., 1995). In the adult liver, E1 and E2 are active in all
hepatocytes while E3 is active only in hepatocytes around the central vein (Peyton et al.,
2000b).
We observed enrichment for histone modifications indicative of active
transcription from promoter and enhancers, including: H3K4me1, H3K4me3, H3K9ac,
and H3K27ac (Figure 4-1). The marks include H3K4me3 and H3K9ac that identify
active promoters and a signal for H3K4me1, which is indicative for active enhancers in
the absence of H3K4me3. Moreover, we observed a signal for H3K27ac, which
associates with active promoters and enhancers (Raney et al., 2014). The gene
downstream of AFP, Afm, is expressed in adult liver and the promoter, but enhancers
have not been characterized (Liu et al., 2011). Since the transcription start site of asAFP
is located ~2kb upstream of the Afm gene, it was possible that the DNA sequence
driving asAFP transcription was also an enhancer of Afm transcriptional activity. To
determine whether asAFP is transcribed by a standard promoter or originate as
enhancer-associated RNAs (eRNAs), a 940 bp DNA fragment from BALB/c genomic
DNA, spanning the region -830 to +112 bp relative to the asAFP TSS was PCR amplified
and inserted into two different pGL3 luciferase plasmid vectors. One contains no
transcriptional control elements and will detect promoter activity present in the inserted
fragment while the other vector contains an SV40 early promoter and will detect
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enhancer activity (Figure 4-2, top panel). I used the mouse liver hepatoma cell line,
Hepa 1.6, as a model to study the functional and molecular characteristics of the mouse
asAFP promoter. The Hepa 1.6 cells, derived from the BW7756 mouse hepatoma cells
that arose from a C57/L mouse, secretes several serum albumin proteins including AFP,
Albumin (Alb), alpha 1 antitrypsin (alpha-1-antitrypsin) and Amylase (Darlington et al.,
1980). I transiently transfected the asAFP-luciferase plasmids into Hepa 1.6 cells with a
Renilla luciferase-expressing control vector to normalize for variation in transfection
efficiency. Luciferase and Renilla values were measured and compared to the control
promoter-less and SV40 promoter vectors. The asAFP DNA segment increased
luciferase levels 4-fold compared to the promoter-less plasmid, showing that this
element had promoter activity. In contrast, this element did not affect the expression of
the SV40 promoter, indicating that it does not have enhancer activity. Thus, asAFP RNA
cannot be considered an eRNA and I have identified a fragment that has promoter
activity (Figure 4-2, bottom panel).
Analysis of asAFP promoter region
To further localize the asAFP promoter activity, I constructed a series of 5′
deletions of the -830 to +112 promoter in the pGL3 basic luciferase vector (Figure 4-3,
top panel). The asAFP promoter luciferase plasmids were transiently transfected into
Hepa 1.6 cells and their luciferase activity was analyzed, as previously described. The
5’ deletion constructs showed no significant differences in promoter activity; the -90 to
+112 construct maintained activity, suggesting that this segment contains the active
promoter sequences that are important for asAFP expression (Figure 4-3, bottom panel).
I also measured asAFP promoter activity in different cell lines including human
embryonic kidney 293 (HEK 293) and the human hepatoma cell lines Hep3B and
HepG2. The trends of transcriptional activity in all cells were similar to those observed in
the Hepa 1.6 cells (data not shown).
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Identification of asAFP core promoter elements
To identify the regulatory elements that influence asAFP expression, I used the
core promoter element prediction tool, ElemeNT (http://lifefaculty.biu.ac.il/gershontamar/index.php/resources) to search for potential core promoter elements within the
asAFP promoter (-90 to +112) sequence. The ElemeNT tool uses experimentallyvalidated sequences with known biological functions to predict core promoter elements
(Sloutskin et al., 2015). Based on this analysis, the asAFP promoter contains predicted
Inr and DPE elements in the region of the identified transcription start site (Figure 4-4A).
Since the asAFP -90Pluc maintained promoter activity, I examined the minimal
sequences required for full promoter activity by measuring promoter activity of a 154 bp
DNA region containing the asAFP promoter inserted into the pGL3 basic luciferase
reporter vector to generate asAFP-42Pluc. Transcription driven by the asAFP-42Pluc
declined relative to the -90 and -175 constructs, but did retain substantial promoter
activity, suggesting important core promoter regulatory element(s) lie within this region
(Figure 4-4C). To examine the function of the predicted Inr and DPE elements, additional
constructs were generated that further reduced the size of the promoter-containing
fragment (Figure 4-4 B). I compared luciferase activity of intact asAFP promoters with
constructs that contain sequence deletions up to position +29 within the DPE. Disruption
of the DPE element significantly decreased the -175 to +29 promoter activity by ~2-fold,
while the asAFP -42 to +29 promoter activity was also reduced by ~2-fold, resulting in
loss of promoter activity (Figure 4-4C). These results indicate asAFP transcription is
driven by a DPE-dependent promoter and the sequences within the DPE element are
critical for full promoter strength. In addition, an element between -90 and -42 likely also
contributes to promoter activity.
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Zhx2 does not regulate the asAFP promoter
Previous studies showed that Zhx2 negatively regulates AFP, Cyclin A and
Cyclin E promoters (Shen et al., 2008; Yue et al., 2012). However, a recent study
showed that Zhx2 activates several of the mouse urinary protein (Mup) promoters,
suggesting that Zhx2 may be a positive and negative transcriptional regulator of target
genes (Jiang et al., 2017). During mouse liver development, both asAFP RNA and Zhx2
mRNA expression increases after birth, raising the possibility that asAFP is positively
regulated by Zhx2. To determine whether Zhx2 regulates the asAFP promoter, I cotransfected the asAFP -830P luc plasmid with a pcDNA plasmid expressing Zhx2 using a
1:3 (luciferase:driver) ratio in Hepa 1.6 cells. I used the pGL3 promoter-less and
Mup20p-luc plasmids as negative and positive controls, respectively. Data in Figure 4-5
shows the expression of Zhx2 increased Mup promoter activity about 1.5-fold, while no
affect is observed on asAFP -830P promoter activity. Since a consensus Zhx2 binding
site has not been identified for its targets genes, I explored Zhx2 regulation of an
extended sequence of the asAFP promoter. A 2-kb region containing the asAFP
promoter (-2160 to +112) was inserted into the pGL3 basic promoter-less luciferase
reporter vector, to generate asAFP -2160Pluc. When I co-transfected the asAFP 2160Pluc with Zhx2, there was still no effect on luciferase expression (Figure 4-5). I
tested several other asAFP promoter luciferase constructs with a range of Zhx2 plasmid
ratios (1:0.5 to 1:10) in multiple cell lines (HEK293, HepG2, Hep3B), but did not observe
any changes in promoter activity (data not shown). Although I observed a correlation
between Zhx2 and asAFP in mice, my in vitro data indicates that Zhx2 does not appear
to be involved in regulating the asAFP promoter.
Discussion
In this chapter, I showed that asAFP transcriptional activity is driven by a
standard promoter and not an enhancer, as is the case with eRNAs. Deletion analysis
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of the asAFP promoter identified the regulatory regions that are important for asAFP
transcriptional activity. There was no significant difference in activity between the
promoter fragment beginning at -830 and the 5’ deletion constructs down to -90. Since
the asAFP 5’ deletion constructs displayed similar promoter activity, I performed
computational analysis that identified an Inr and DPE element that comprise the asAFP
core promoter. I tested the function of predicted core promoter elements by comparing
activity of asAFP promoters that contained the deletions of the DPE sequences up to
position +29. Mutational analysis showed that transcription driven by the asAFP
promoter (-175 to +29) resulted in ~2 -fold reduction in promoter activity, while a
complete loss of activity was observed in the -42 to -29 promoter. My data clearly
demonstrates that the asAFP promoter requires an intact DPE sequence that is
important for full promoter strength and transcription initiation.
Previous studies suggest Zhx2 is a transcriptional regulator of target genes; yet
the mechanism by which Zhx2 regulates target gene expression is not fully understood.
We previously showed the expression of asAFP RNA and Zhx2 are positively correlated
in animals expressing normal and low levels of Zhx2. In addition, data from others in the
Spear and Peterson lab indicate asAFP and Zhx2 transcript levels are positively
correlated during liver development, suggesting asAFP may be a potential target of
Zhx2. However, when a pcDNA plasmid expressing Zhx2 was co-transfected the
asAFP830P luc plasmid, Zhx2 had no effect on promoter activity. I also cloned a larger
promoter fragment, in case a Zhx2 responsive site was located further from the start site.
However, consistent with the asAFP830P results, I did not observe changes in promoter
activity, suggesting Zhx2 does not regulate asAFP transcriptional activity.
Multiple liver-enriched transcription factors are involved in the regulation of
hepatic gene expression, such as the hepatic nuclear factors (HNFs), CCAAT/enhancerbinding protein beta (C/EBP), and D-binding protein (DBP) (Schrem et al., 2002). To
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identify potential liver-enriched transcription factors that may regulate asAFP promoter
activity, I used the JASPAR transcription factor (TF) prediction program
(jaspar.genereg.net) to screen for potential binding sites in the asAFP -90 to +112
promoter sequence. Several predicted TF’s were identified, including putative binding
sites for Transcription Factor 4 (TCF4), Hepatocyte nuclear factor 4 alpha (HNF4a), and
Nuclear factor 1 alpha (NF1a). I examined their effect on the asAFP promoter by cotransfecting the -90Pluc promoter with individual pcDNA plasmids expressing TCF4,
HNF4a, and NF1a into Hepa 1.6 cells. My preliminary data suggested that the
expression of HNF4a and NF1a did not influence asAFP promoter activity, whereas
TCF4 reduced promoter activity (data not shown). Curiously, the predicted TCF4 binding
site is within the Inr motif of the asAFP promoter, suggesting TCF4 binding may interfere
with initiation of asAFP transcription. However, the mechanism by which TCF4
influences asAFP transcriptional repression will require further investigation.
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Figure 4-1. ENCODE tracks from ChIP-seq data of the AFP/asAFP/Afm genomic region.
Histone tracks for the following chromatin modification marks for active promoters
(H3K4me3, H3K9ac) enhancers (H3K4me1, in the absence of H3K4me3) or
promoters/enhancers (H3K27ac) were extracted from the publicly available data
(http://genome.ucsc.edu/). The transcriptional directions of the genes and asAFP are
shown; the asAFP exon 1 is identified and corresponds to a clear peak of histone
modifications. Two of the three well-characterized AFP enhancers (E1, E2) are also
identified (Raney et al., 2014).
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Figure 4-2. Identification of the asAFP promoter. Top panel. Schematic of asAFP
putative promoter/enhancer cloning strategy. Bottom panel. A 940 bp fragment of
asAFP predicted promoter/enhancer from -830 to +112 was cloned upstream of
luciferase in the promoter-less and SV40 early promoter pGL3 luciferase plasmids. The
luciferase constructs were transfected together with TK-Renilla, which served as an
internal control for transfection efficiency, into Hepa 1.6 cells. pGL3-basic and pGL3SV40-promoter were also transfected as controls. 48 hours later, the relative luciferase
values were determined. The promoter activity is expressed relative to the activity of the
pGL3 basic and pGL3 promoter luciferase vectors. The results represent the mean +/SD of 8 independent transfections, *** p < 0.001.
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Figure 4-3. Deletion analysis of the asAFP promoter. (A) Schematic illustration of a
series of 5’ deletions of the mouse asAFP promoter. (B) asAFP 5’ deletion promoter
luciferase constructs were transfected together with TK-Renilla into Hepa 1.6 cells that
served as an internal control for transfection efficiency. 48 hours later, the relative
luciferase values were determined. The promoter activity is expressed relative to the
activity of the pGL3 basic luciferase vector. The results represent the mean +/- SD of 5
independent transfection experiments.
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Figure 4-4. Identification of the asAFP core promoter elements. asAFP -90 to +112
sequence was used as the input sequence for ElemeNT computational analysis of
asAFP putative core promoter elements (http://lifefaculty.biu.ac.il/gershontamar/index.php/resources). (A) Schematic of asAFP predicted core promoter elements.
(B) Schematic illustration of the intact asAFP promoter (-175 to +112) and deletion
constructs (-42 to +112), (-175 to +29) and (-42 to +29). (C) asAFP promoter constructs
were transfected together with TK-Renilla into Hepa 1.6 cells that served as an internal
control for transfection efficiency. 48 hours later, the relative luciferase values were
determined. The promoter activity is expressed relative to the activity of the pGL3 basic
luciferase vector and was set to 1. The results represent the mean +/- SD of 3
independent transfection experiments, ** p <0.01, *** p < 0.001.
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Figure 4-5. Zhx2 does not regulate the asAFP promoter. Hepa 1.6 cell were
transfected with pGL3 basic, -830P-Luc, -2160P-Luc or Mup20p-Luc reporter genes along
with pcDNA 3.1 empty vector or the Zhx2 expression vector at a 3:1
ratio; Renilla luciferase was also included to control for variations in transfection
efficiency. After 48 hrs, cells were harvested, and lysates were analyzed for
firefly/Renilla luciferase. The asAFP -830 and -2160 promoters were not responsive to
Zhx2, while the Mup20 promoter was activated by Zhx2. The results represent the mean
+/- SD of 3 independent transfection experiments, *** p < 0.001.

Copyright © Maria S. Dixon 2017

67

CHAPTER V
CHARACTERIZATION OF asAFP RNA MECHANISM OF ACTION

LncRNAs have gained widespread attention in recent years as new and
potentially crucial biological regulators. While only a small number of lncRNAs have
been fully characterized to date, it is believed that lncRNAs are involved in a range of
developmental processes and diseases. Understanding the mechanisms by which
lncRNAs act is still surprisingly limited. It is estimated that more than 70% of mammalian
sense transcripts have antisense partners, suggesting a central role of antisense
transcripts in regulating eukaryotic gene expression (Kung et al., 2013). Several studies
have shown antisense RNAs can negatively or positively modulate expression of their
overlapping sense transcript in cis or in trans at the transcriptional and
posttranscriptional level (Pelechano and Steinmetz, 2013). There are several proposed
mechanisms by which antisense RNAs can regulate their sense partner, including
transcriptional interference, epigenetic modification and chromatin remodeling.
Additionally, the genomic arrangement of some antisense RNAs allow them to base pair
with their sense partner mRNAs in the nucleus or cytoplasm to potentially regulate
processes such as RNA stability, transport and translation (Cech and Steitz, 2014;
Mahmoudi et al., 2016; Pelechano and Steinmetz, 2013; Wilusz et al., 2009).
Antisense RNAs that regulate gene expression in the nucleus can alter
transcription, modulate alternative splicing or recruit editing enzymes to dsRNAs, leading
to alterations in subcellular localization, transport and RNA stability (Faghihi and
Wahlestedt, 2009). For example, the expression of antisense RevErbAα inhibits splicing
of the thyroid hormone receptors isoforms, TRα2 and TRα1. The interaction between
RevErbAα and TRα2, negatively regulates TRα2 mRNA expression, which alters the
balance and function of the two isoforms (Hastings et al., 1997). Antisense RNAs have
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been linked to influencing mRNA editing by altering RNA structure, coding potential, or
stability. In Drosophila melanogaster, the interaction between 4f-rnp (RNA-binding
protein 4F) mRNA and its antisense sas-10 recruits adenosine deaminases that act on
RNA (ADAR) enzymes that convert adenosines to inosines (A-to-I) in the overlapping
region. A-to-I RNA editing decreased 4f-rnp mRNA abundance by decreasing the
stability of the 4f-rnp mRNA (Peters et al., 2003).
Antisense RNAs that regulate gene expression in the cytoplasm are mainly
involved in modulating processes such as mRNA stability or translation (Faghihi and
Wahlestedt, 2009). For instance, the formation of the RNA duplex between BACE1-AS
and BACE mRNA masks the binding site for miR- 485-5p, resulting in an increase of
BACE mRNA stability (Faghihi et al., 2010). In contrast, antisense RNAs can facilitate
the degradation of mRNAs by promoting Staufen-mediated mRNA decay (SMD) via
binding of Stau1 dsRNA binding protein. Gong and Maquat demonstrated that Stau1
binding sites are formed by imperfect base-pairing between an Alu element in the 3’UTR
of the target mRNA and another Alu element in a cytoplasmic, poly-adenylated lncRNA
(1/2-sbsRNA) that recruits Stau1 for mRNA degradation (Gong and Maquat, 2011).
Antisense RNAs can also promote or repress translation of target mRNAs. Carrieri, et al.
demonstrated that cellular stress conditions caused the nuclear antisense ubiquitin
carboxy-terminal hydrolase L1 (AS Uchl1) RNA translocation to the cytoplasm where it
bound to the 5’ end of Uchl1 mRNA to increase translation (Carrieri et al., 2012).
Conversely, it has been reported that lincRNA-p21 inhibits translation of CTNNB1 (βcatenin) and JUNB transcripts through imperfect base pairing with several sites in the
coding and UTRs of both transcripts (Huarte et al., 2010). Despite the widespread
attention lncRNAs have gained in recent years, the full extent of their biological
significance is not well understood (Kung et al., 2013). We have identified novel
antisense AFP (asAFP) RNA transcripts that partially overlap the 3’ half of the mouse
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AFP gene. AFP mRNA and asAFP RNA are co-expressed in the adult mouse liver and
are inversely correlated in the presence or absence of Zhx2. This suggests a regulatory
connection between these two RNAs, which will be examined here.

Results
asAFP RNA regulates AFP in trans
To investigate whether asAFP regulates AFP mRNA expression, various asAFP
expression constructs that together cover the full-length asAFP transcript were
generated as shown in Figure 5-1A. As a negative control, a segment of an Igm Cµ
intron was inserted into pcDNA expression vector. These constructs were transiently
transfected in Hepa 1.6 cells and changes in endogenous AFP mRNA was measured by
RT-qPCR. To confirm the expression of asAFP RNAs, I analyzed Hepa 1.6 cells
transfected with asAFP constructs by RT-qPCR using asAFP-specific primers. To avoid
amplification of contaminating plasmid DNA, total RNA was treated with RNase-free
DNase I and reverse transcribed. As controls, a no reverse transcription (NRT) and no
template controls (NTC) were used to confirm the absence of contamination. Expression
of transfected asAFP RNA segments was detected in transfected Hepa 1.6 cells
although the levels varied among experiments (Figure 5-1B). Interestingly,
overexpression of all segments of asAFP RNA significantly decreased endogenous AFP
mRNA levels, while with IgM expression, levels were not affected (Figure 5-1C). These
results suggest asAFP negatively regulates AFP mRNA expression in trans.
Because all asAFP RNA constructs downregulated AFP mRNA to similar levels,
I utilized flow cytometry analysis to separate the transfected cells that express asAFP
RNA from the untransfected cells using a plasmid expressing Green Fluorescent protein
(GFP) as a reporter. The asAFP mid expression construct was co-transfected with GFP
plasmid into Hepa 1.6 cells. As negative controls, cells were co-transfected with pcDNA
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empty vector-GFP and an expression vector that contains AFP exons 9-14 (+) cDNAGFP in the sense orientation. Since changes in endogenous AFP mRNA is measured
using primers in AFP exons 1 and 2, the expression of AFP e9-14(+) plasmid
should not affect AFP mRNA expression or detection. 48 hrs after transfection, cells
were harvested and sorted into GFP-positive and GFP-negative populations and
endogenous AFP mRNA levels in each were analyzed by RT-qPCR. Flow analysis
showed that 49%, 34%, and 40% of cells transfected with pcDNA, asAFP mid, and AFP
e9-14 (+), respectively were GFP positive (Figure 5-2A). Consistent with my previous
transient transfection data, the expression of asAFP mid plasmid reduced AFP mRNA
levels in the unsorted population, while expression of AFP exon 9-14(+) did not affect
AFP mRNA expression, as expected (Figure 5-2B). The asAFP mid-expressing GFP
positive cells showed reduced AFP mRNA levels in comparison to the unsorted
transfected cells, whereas the GFP-negative cells did not have decreased AFP mRNA
levels (Figure 5-2B). When the data was plotted to compare the AFP mRNA from the
GFP+ and GFP- populations from a single sort experiment, the asAFP mid plasmid
substantially decreased of AFP mRNA levels (Figure 5-2C). These findings confirm that
asAFP RNA downregulates AFP mRNA expression because the reduced endogenous
AFP mRNA is only seen in the cells that are actually transfected with the asAFP
constructs.
asAFP does not regulate neighboring genes
AFP is a member of the serum albumin gene family that is comprised of albumin,
alpha-fetoprotein, alpha-albumin (afamin), and the more distantly related Vitamin D
binding protein (Peterson et al., 2011). These genes arose from a common ancestor
through a series of duplication events, and are expressed primarily in the liver
(Alexander et al., 1984; Naidu et al., 2010). AFP is part of a gene cluster, with the
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neighboring genes Alb and Afm located 14.1 kb upstream and 10.0 kb downstream of
the AFP gene, respectively (Figure 5-3A). Some antisense RNAs can mediate
widespread transcription to modulate the expression of neighboring genes in cis or trans
by the act of transcription or through the recruitment of chromatin-modifying complexes,
such as Polycomb repressive complex 2 (PRC2) to genomic loci (Pelechano and
Steinmetz, 2013). To test the extent of asAFP mediated regulation, I analyzed changes
in AFP, Afm and Alb mRNA levels in liver RNA from multiple sets of adult C57/Bl6 wildtype (Zhx2 +/+) and whole-body Zhx2 knock-out (Zhx2 -/-) littermate mice. As expected,
AFP mRNA levels were lower in the presence of Zhx2, while asAFP RNA levels were
higher in the presence of Zhx2. Alb and Afm mRNA levels were not affected by the
status of Zhx2 or differences in asAFP RNA in the mice (Figure 5-3B). I also measured
changes in AFP, Alb, and Afm mRNA after overexpressing the asAFP mid expression
construct in Hepa 1.6 cells (Figure 5-4). My data show that while elevated expression of
asAFP significantly reduced AFP mRNA levels, Afm and Alb mRNA levels were not
affected. Together, my in vivo and in vitro data demonstrate that asAFP does not
regulate the expression the neighboring albumin genes and confirms the specificity of
asAFP’s downregulation of AFP mRNA.
asAFP segments that overlap with exons more effectively repress AFP
Because all asAFP RNA segments were able to downregulate AFP mRNA, I
further examined which segments may be more effective in AFP downregulation. I
analyzed whether the portions of asAFP RNAs that overlap with AFP introns or exons
were more effective in decreasing AFP mRNA levels. If the sequences of asAFP RNA
that can base-pair with AFP introns are more active, this would likely require the
regulatory mechanism to occur in the nucleus before the AFP mRNA is processed. If,
however, the portion of the asAFP RNA that can base-pair with the AFP exons is more
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active, this means the regulation likely occurs after mRNA processing and before or
during cytoplasmic accumulation. Using the asAFP mid pcDNA construct, I performed
PCR mutagenesis to remove the exon 12 sequences (delta e12) and also generated a
pcDNA plasmid that expresses just exon 12 in the antisense orientation, (e12-) (Figure
5-5 A). The delta e12 expression plasmid contains the overlapping intron sequences and
the e12- expression plasmid contains the overlapping exonic sequences from the
original asAFP mid construct. I transiently transfected these plasmids into Hepa 1.6
cells along with the starting asAFP mid plasmid and pcDNA empty vector control and
measured endogenous AFP mRNA levels by RT-qPCR. As previously described, the
expression of asAFP RNAs were confirmed by RT-qPCR and exhibited higher
expression levels than the pcDNA control (Figure 5-5B). Figure 5-5C shows that
expression of both delta e12 and e12 (-) constructs significantly downregulated
endogenous AFP mRNA. However, the construct that overlaps the exon, e12(-), had a
greater effect on AFP mRNA downregulation than the construct that overlaps the intron
sequences, suggesting this regulation possibly occurs during nuclear export or in the
cytoplasm.
I also separated the transfected cells that express asAFP from untransfected
cells by flow cytometry as previously described. I co-transfected this set of asAFP RNA
plasmids with a plasmid expressing GFP in Hepa 1.6 cells. As negative controls, cells
were transfected with pcDNA empty vector-GFP empty vector. 48 hrs after
transfection, the cells were sorted into GFP-positive and GFP-negative populations by
flow cytometry and endogenous AFP mRNA levels in each were analyzed by RT-qPCR.
Flow analysis showed that 50% to 60% of cells transfected with the pcDNA, asAFP mid,
delta e12, and e12 (-) expression plasmids were GFP positive (Figure 5-6A). In both the
unsorted and sorted GFP+ populations, delta e12, and e12 (-)-transfected samples
decreased AFP mRNA to similar levels (Figure 5-6B). Curiously, the GFP- populations
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showed higher levels of AFP mRNA compared to the pcDNA empty vector control
(Figure 5-6B). However, when I plotted the data to compare the AFP mRNA from the
GFP+ and GFP- populations from this single sort experiment, while all the asAFP
plasmids substantially decreased AFP mRNA, e12 (-) showed a marginally greater
decrease than delta e12 (Figure 5-6C). Together, my data suggest that the
complementary regions between AFP mRNA and asAFP RNA may contribute to AFP
mRNA downregulation and the overlapping exonic sequences are more effective.
RNA editing of AFP and asAFP complementary regions
To explore the possibility that asAFP regulates AFP by affecting mRNA decay, I
tested whether overlapping sequences of AFP and asAFP RNA form dsRNA duplexes
that could serve as substrates for A-to-I RNA editing by ADAR. A-to-I edited sites can
be detected as A>G conversions in cDNA. To investigate the possible role of RNA
editing, we examined the sequences of the cDNA clones that were generated to
characterize the extent of asAFP genomic structure. These clones were generated by
RT-PCR from adult liver RNA of BALB/cJ mice that express the Zhx2 transgene but did
not use a high-fidelity polymerase. To distinguish between RNA editing changes and
DNA polymorphisms, we screened for unique edited sites in one clone that did not
appear in another and mapped the sequences to the compiled asAFP cDNA sequence.
This analyses identified four potential A>G changes due to editing distributed randomly
throughout on the antisense strand (Figure 5-7, above dashed line). This observation
led me to determine whether ADAR activity may result in RNA editing throughout the
complementary sequences between AFP and asAFP. Although editing mostly occurs in
noncoding regions such as UTRs or introns, a small fraction of editing occurs in coding
regions that could change amino acid sequences. Because my data suggest that the
overlapping exons are likely more effective in mRNA downregulation, I examined the
presence of editing in the sequences that overlap with AFP exons 9-14. I used a high74

fidelity DNA polymerase enzyme in the PCR reactions to avoid mutations introduced
during the amplification, followed by cloning and Sanger sequencing. In addition, to
control for possible errors introduced by DNA polymerase infidelity, I used the lowest
number of PCR cycles that resulted in detectable PCR products. My sequencing
analysis of 51 cDNA clones did not show any evidence of sequence differences that
could be attributed to RNA editing in the AFP coding regions (Figure 5-7). I also
assessed the presence of A-to-I RNA editing in the AFP/asAFP overlapping genomic
regions, focusing on those where potential A>G changes were observed previously in
single clones. I generated multiple cDNA segments within the overlapping sequences
between AFP and asAFP transcripts (Figure 5-7). My analysis of 142 cDNA clones that
spanned ~600 bp to >2kb sequence overlap did not show any indication A>G sequence
changes, but did detect two clones with T>C conversions, suggesting editing on the
antisense RNA strand of the sense-antisense duplex. After second-strand cDNA
synthesis during PCR, these sites would then be visualized as T>C conversions on the
antisense strand (Peters et al., 2003). Additionally, I found multiple single nucleotide
polymorphisms (SNPs) within these regions; however their biological significance is
unknown. Previous studies by Peters et al, reported extensive ADAR-mediated RNA
editing within the overlapping regions of Drosophila 4f-rnp and sas-10 transcripts during
embryo development. During development, the frequency of RNA editing detected was
7.8% in the late embryo stage (4/51 clones that covered 162 bp of overlap), increased to
24.4% in adult heads (11/45 clones) and 16.7% in adult bodies (8/48 clones) (Peters et
al., 2003). In contrast, the frequency of potential RNA editing sites found here detected
was 0% of the 23 clones that cover ~600 bp overlap and 7.4% of the 27 clones that
cover more than 2kb of the overlap. The pooled results indicate 2 of the 50 cDNA
clones sequenced had evidence of potential RNA editing on the antisense strand. These
low levels of potential RNA editing prompted me to analyze nuclear cDNA clones in
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attempts to detect higher levels of editing in the AFP/asAFP overlap regions. Again, I
was unable to detect evidence of editing in the 41 cDNA clones that covered more than
2kb of the overlap (Figure 5-7). Even though I can not determine how many unique
transcripts are represented by the multiple clones I sequenced, similar approaches in
other labs have detected higher levels of potentially edited sites. Thus, I conclude form
this analysis that the complementary regions between AFP and asAFP are not
extensively edited by ADAR enzymes.

Discussion
Sense and antisense transcripts can interact through their complementary
regions, resulting in dsRNA that can alter mRNA stability, transport, and translation
(Werner and Sayer, 2009). I show here that overexpression of all segments of asAFP
RNA negatively regulate AFP mRNA expression in trans. Because asAFP RNA is
expressed at very low levels in Hepa 1.6 cells, I utilized this approach to study the
effects of increased levels of asAFP RNA on the endogenous expression of AFP mRNA.
Although overexpression of individual genes has been widely used as a tool for
connecting genes to biological pathways, this approach does not always produce
biologically relevant results and should be confirmed by alternate methods (Prelich,
2012). To complement my overexpression studies, cell lines that stably express asAFP
would allow knock-down studies of asAFP RNA using both siRNA and antisense oligos
(ASO) to measure the changes on AFP mRNA levels. Because siRNAs function mainly
in the cytoplasm and ASO effects depend on nuclear RNase H, these experiments
would further help distinguish whether the regulation of AFP mRNA by asAFP RNA
occurs in the cytoplasm or the nucleus. In attempts to complement my overexpression
experiments, I used G418 as a selection marker to generate stable cells lines
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overexpressing asAFP 5-1 and asAFP mid constructs. However, I was unable to
generate clones that substantially express asAFP RNA when measured by RT-qPCR.
Antisense transcription has been shown to regulate neighboring genes that are
transcribed on the same genomic locus; therefore, I determined whether asAFP RNA
could regulate AFP’s neighboring genes. I showed that the expression of asAFP does
not affect Alb or Afm mRNA levels both in vitro and in vivo, confirming the specificity of
asAFP for AFP mRNA regulation.
My Hepa 1.6 transfection data showed that the expression of various segments
of asAFP RNA decreased AFP mRNA levels. Because only a portion of the cells are
transfected, to confirm my results with representative constructs, I separated transfected
from non-transfected cells by sorting for GFP+ cells. Clearly, AFP mRNA was
downregulated by the asAFP mid construct in the transfected, but not the nontransfected cell populations. As an independent way to identify the cellular location by
which asAFP regulates of AFP mRNA, I examined whether the asAFP sequences that
were complementary to AFP intronic or exonic sequences had a greater effect on AFP
expression. My transient transfection data showed that while both complementary
intronic and exonic sequences downregulated AFP mRNA expression, the exonic
sequences were more effective. Curiously, I observed that the asAFP mid and exon 12
(-) constructs decreased AFP mRNA to similar levels even though the amount of asAFP
sequence in each differ greatly (1800 bp in asAFP mid and 224 bp in e12(-)). One
interpretation of this result is that the exonic sequences, which are the same in these two
constructs, are the active sequences. Together these findings suggest that asAFP RNA
is exerting its effect on AFP mRNA at a step after RNA splicing, possibly during nuclearcytoplasmic transport or in the cytoplasm. Because the segments that overlapped with
intronic sequences decreased AFP mRNA levels, I also explored the asAFP regulation
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of AFP mRNA stability via ADAR mediated RNA editing. I analyzed multiple clones that
contained complementary sequences between AFP and asAFP but there was no
indication of extensive editing in AFP and asAFP dsRNA. Previous studies suggested
ADAR proteins can affect gene expression independently of its deamination activity
(Wang et al., 2013a). Future studies would examine changes in asAFP RNA and AFP
mRNA expression following siRNA-mediated knockdown of the catalytic active ADAR 1
and ADAR 2 enzymes in Hepa 1.6 cells.
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Figure 5-1. asAFP RNA regulates AFP in trans. (A) asAFP pcDNA cloning strategy.
Segments of asAFP cDNA (blue open boxes) that together cover the entire asAFP
transcript were cloned into pcDNA3.1 and transiently transfected into the mouse liver cell
line Hepa-1.6 along with an empty vector (pcDNA). The numbers indicate sizes, in nt, of
the asAFP sequence included in the construct. (B) Total RNA was isolated, DNAsetreated, and reverse-transcribed. The expression of asAFP RNAs and pcDNA control
were measured by RT-qPCR using the asAFP-specific primers indicated and normalized
to ribosomal protein gene L30 mRNA. (C) Endogenous AFP mRNA levels were
analyzed by RT-qPCR 48 hrs after transfection with the asAFP constructs shown and
normalized to L30 mRNA. A segment from the IgM gene cloned into pcDNA was used
as a negative control. The fold-change was determined by comparison of asAFP RNA
levels with those of the pcDNA empty vector control. The results represent the mean +/SD of >7 independent transfection experiments, *** p <0.001.
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Figure 5-2. Sorted cells confirm that asAFP RNA regulates AFP in trans. (A) Density
plots of Hepa 1.6 cells transfected with pcDNA alone (control), or pcDNA, asAFP mid,
and AFP e9-14(+) co-transfected with pEGFP. The GFP+ (red boxes) and GFPnegative (black boxes) cell populations were sorted by flow cytometry. (B) RT-qPCR
analysis of endogenous AFP mRNA levels of unsorted, GFP positive and GFP negative
populations using L30 mRNA as a control. The data were normalized to the pcDNA
empty vector control. (C) Fold-change was determined by comparison of AFP mRNA
levels from GFP-positive sorted cells with those to GFP-negative sorted cells. This data
is from one transfection and sorting experiment; the cDNA was analyzed twice in
duplicates, ** p <0.01.
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Figure 5-3. asAFP does not regulate neighboring genes. (A) Map of the mouse Alb, AFP
and Afm locus, showing the relative position of the asAFP. The location and distance
between the genes are shown, numbers below indicate the size of the genes and
intergenic regions (in kb). (B) AFP, asAFP, Alb, and Afm transcript levels were
measured by RT-qPCR from four sets of adult liver RNA from C57/Bl6 wild-type (Zhx2
+/+, grey bars) and whole-body Zhx2 knock-out (Zhx2 -/-, blue bars) littermate mice.
Ribosomal protein L30 was used as an internal control, *p <0.05, *** p<0.001.
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Figure 5-4. Overexpression of asAFP does not affect the expression of Alb and Afm.
Map of the AFP gene from exon 7 to about 7 kb downstream of exon 15. Above the line
are the AFP exons (open boxes) and below are the asAFP exons (grey boxes). Top
panel. Schematic of asAFP RNA and relative location of Alb and Afm (not drawn to
scale). Bottom panel. asAFP mid pcDNA construct and pcDNA empty vector control
were transiently transfected in Hepa 1.6 cells. Alb, AFP, and Afm mRNA levels were
measured by RT-qPCR. Ribosomal gene L30 was used as a normalizing control for all
samples. The results represent the mean +/- SD of 3 independent transfection
experiments, * p <0.05
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Figure 5-5. Exonic regions more effectively repress AFP mRNA. (A) Schematic of
pcDNA cloning strategy to generate segments that overlap AFP intron and exonic
sequences. Single primer mutagenesis was performed to remove exon 12 sequences
from the asAFP mid pcDNA3.1 construct and to make a pcDNA construct that expresses
just sequences that are antisense to exon 12. The numbers indicate sizes of the asAFP
sequence included in the construct. Plasmids were transfected into Hepa 1.6 cells along
with pcDNA empty vector control and the asAFP mid parental expression vector. (B)
Total RNA was isolated, DNAse-treated, and reverse-transcribed. The expression of
asAFP RNAs and pcDNA control were measured by RT-qPCR using the asAFP-specific
primers indicated and normalized to ribosomal protein gene L30 mRNA. The fold-change
was determined by comparison of asAFP RNA levels with those of the pcDNA empty
vector control. (C) Endogenous AFP mRNA levels, relative to L30 mRNA, were analyzed
by RT-qPCR. The fold-change was determined by comparison of asAFP RNA levels with
those of the pcDNA empty vector control. The results represent the mean +/- SD of > 7
independent transfection experiments, *** p< 0.001.
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Figure 5-6. Cell sorting to compare effectiveness of overlapping exonic and intronic
regions of AFP mRNA. (A) Density plots of Hepa 1.6 cells transfected with pcDNA alone
(control), or pcDNA, asAFP mid, delta e12 and e12 (-) co-transfected with pEGFP. The
GFP-positive (red boxes) and GFP-negative (back boxes) cell populations were sorted
by flow cytometry. (B) RT-qPCR analysis of endogenous AFP mRNA levels of unsorted,
GFP positive and GFP negative populations using L30 mRNA as a control. The data
were normalized to the pcDNA empty vector control. (C) Fold-change was determined
by comparison of AFP mRNA levels from GFP-positive sorted cells with those to GFPnegative sorted cells. This data is from one transfection and sorting experiment; the
cDNA was analyzed twice in duplicates, *** p< 0.001.
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Figure 5-7. Identification and distribution of RNA editing in AFP mRNA and asAFP RNA
overlapping region. Map of the AFP gene from exon 7 to about 7 kb downstream of exon
15. Above the line are the AFP exons (open boxes) and below are the asAFP exons
(grey boxes). The transcriptional orientation of the two transcription units is shown above
the map. RNA editing sites showing the location of each A>G (green) or T>C (red)
conversion. The open black box represents the segment that was cloned and
sequenced. A description of the primers used for PCR amplification, amplicon size, the
number of changes and the number of clones examined are indicated on the right.
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CHAPTER VI
SUMMARY AND FUTURE DIRECTIONS

LncRNAs have emerged as important regulators of gene expression. While only
a small number of lncRNAs have been fully characterized, several are involved in
various developmental processes and diseases, including HCC (Prensner and
Chinnaiyan, 2011; Yu et al., 2015). The data reported in this dissertation contributes to
the understanding by which antisense RNAs control the expression of developmental
genes that are misregulated in liver cancer. The AFP gene was used as the model
biological system to study gene regulation. Previous studies suggested that Zhx2
functions as a transcriptional repressor of AFP postnatal expression through the AFP
promoter (Peyton et al., 2000a). However, despite differences in steady state AFP
mRNA levels in adult livers of BALB/cJ and wild-type mice, the transcription rates across
the AFP gene were similar between the two strains of mice (Morford, unpublished;
Vacher et al., 1992). This result is not consistent with Zhx2 being a transcriptional
repressor. Thus, based on this observation, it was proposed that Zhx2 functions in a
promoter-dependent manner but acts at the post-transcriptional level, perhaps by
connecting a transcriptional to a post-transcriptional step of gene expression. To date,
the mechanism by which Zhx2 regulates AFP is not well understood; it is also not yet
clear if AFP is a direct target of Zhx2. Other genes, such as H19, Gpc3, Lpl, and several
Cyp genes (Creasy et al., 2016; Gargalovic et al., 2010; Morford et al., 2007; Pachnis et
al., 1984), are also differentially expressed in the presence or absence of Zhx2; which of
these are direct or indirect targets of Zhx2 is not yet clear. There is evidence from our
lab that Zhx2 positively regulates Mup genes through a site about 800 bp upstream of
the promoter(Jiang et al., 2017). How Zhx2 may act to activate some genes and repress
others is not known.
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While studying the mechanism by which Zhx2 regulates AFP, our studies
identified novel unannotated asAFP transcripts transcribed on the opposite strand of the
AFP gene. In this work, I characterized asAFP RNAs and their role in regulating AFP
gene expression. asAFP RNAs are ~5kb alternatively spliced transcripts containing 2-4
exons that partially overlap the 3’ half of AFP. Analysis of asAFP’s largest predicted
open reading frame (ORF) and coding potential suggest that asAFP is a noncoding
RNA. In addition, my data suggest that asAFP RNAs are not conserved with no
evidence of sequence homology with other species, which is consistent with the idea
that lncRNAs are generally less conserved than protein-coding genes (Derrien et al.,
2012). Moreover, the asAFP transcription initiation region exhibits marks for active
promoters and enhancers. Therefore, I examined asAFP transcriptional regulation and
showed that asAFP is driven by a standard promoter comprised of an Inr and DPE motif
that are required for full promoter strength. Because asAFP expression is positively
correlated with Zhx2 in adult mouse liver and during liver development, I examined
whether Zhx2 regulates the asAFP promoter. However, despite using multiple promoter
constructs, multiple ratios of promoter to Zhx2 plasmid and multiple different cell lines, I
found no evidence that Zhx2 was able to regulate the asAFP promoter. Although Zhx2
may not directly regulate asAFP, data shown here indicated that AFP and asAFP are coexpressed in mouse liver and their expression is inversely correlated in adult littermate
Zhx2 wild-type and Zhx2 mutant mice and during liver development. Based on these
findings, I hypothesized that asAFP contributes to the developmental regulation of AFP
gene expression.
LncRNAs are emerging as new players in developmental and cancer paradigms,
demonstrating their potential roles in embryonic development and both oncogenic and
tumor suppressive pathways. These novel transcripts are frequently overexpressed in
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cancer cells in comparison to normal tissue of the same origin, suggesting lncRNAs may
be used as diagnostic markers or potential therapeutic targets in the treatment of cancer
(Braconi et al., 2011; Matouk et al., 2007; Panzitt et al., 2007). Curiously, my data
indicated that asAFP RNA expression levels were not altered in HCC tumors compared
to non-tumor tissues, suggesting that asAFP RNA may not be directly involved in AFP
misregulation in liver cancer. The rise of HCC in the United States has been linked to
chronic hepatitis and more recently to NAFLD that can lead to hepatic fibrotic scarring
that can interfere with normal liver function. Extensive hepatic damage can progress to
cirrhosis and declining liver function (Baffy et al., 2012; El-Serag and Rudolph, 2007).
Because the progression of HCC occurs through a step-wise process, future studies will
examine changes in asAFP expression in a liver fibrosis model. Studies from others in
the Peterson lab demonstrated that the expression of AFP and asAFP are inversely
correlated during liver development, suggesting that asAFP may contribute to AFP
repression during postnatal development. During fetal liver maturation, the function of
the liver significantly changes from a hematopoietic organ to a metabolic organ (SiTayeb et al., 2010). While the roles of lncRNAs in liver development are not understood,
one hypothesis is that developmental cues may induce asAFP RNA expression. A better
understanding of how asAFP expression is regulated may provide insight into a
mechanism by which asAFP contributes to AFP mRNA regulation during liver
maturation.
Here, I showed that asAFP acts as a negative regulator of AFP mRNA
expression mediated possibly through a base-pairing mechanism. Antisense RNAs are
functionally diverse and can potentially regulate target genes at the transcriptional,
posttranscriptional, and translational level (Figure 1-3). At the transcriptional level, the
act of transcription in the antisense orientation can affect gene regulation through
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transcriptional collision of RNA polymerases on convergent genes (Prescott and
Proudfoot, 2002). However, several lines of evidence suggest that transcriptional
interference is not involved in asAFP regulation of AFP which includes: 1. asAFP and
AFP are co-expressed in mouse tissues 2. Data from nuclear run-on assays
demonstrated that transcription rates of AFP from adult littermate Zhx2 wild-type or Zhx2
mutant mice that were similar. Studies done by others in our lab analyzed splicing
across the AFP gene using liver RNA from adult BALB/cJ littermates with or without the
Zhx2 transgene. These studies did not find evidence of alternatively spliced AFP
transcripts, thus eliminating asAFP’s role in regulating alternative splicing. Also, lncRNAs
have been shown to alter local chromatin modifications to affect gene expression within
a specific chromosomal domain (Gupta et al., 2010; Kotake et al., 2011). I have no
evidence that asAFP affects either of AFP’s neighboring genes, so this is an unlikely
mechanism of action.
Previous studies showed the formation of nuclear sense- antisense transcripts
could be edited by adenosine deaminases, which convert adenosine residues into
inosines, leading to codon changes, nuclear retention, or alterations in mRNA stability
(Peters et al., 2003). I proposed that AFP and asAFP RNA/RNA duplexes may form and
serve as substrates for ADAR mediated decay. While I anticipated potential RNA editing
within the complementary regions would lead to AFP mRNA degradation, the detected
low levels of nucleotide changes attributed to editing suggests that ADAR activity does
not appear to play a role in AFP mRNA stability. Recent studies suggest that ADAR
enzymes can affect gene expression independently of their deamination activity.
Following ADAR1 knockdown in human B cells, the expression of zinc-finger proteins
were altered, without being edited (Wang et al., 2013a). Based on this finding, future
studies would examine ADAR effects on AFP and asAFP expression.
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As previously mentioned, the expression of various sized asAFP segments that
together cover the full-length transcript downregulated AFP mRNA to similar levels. To
better understand asAFP regulation, I examined whether the asAFP segments that
overlapped with AFP intronic or exonic sequences were more effective. Although both
overlapping intronic and exonic segments significantly decreased AFP mRNA, my data
showed that overlapping exons had greater activity. This data suggests that asAFP
regulation of AFP possibly occurs after nuclear export in the cytoplasm, which is
correlative with other studies in my lab that showed asAFP RNA accumulated higher in
the cytoplasm compared to the nucleus. In addition, the difference in AFP mRNA
accumulation in the presence or absence of Zhx2 was observed more prominently in the
cytoplasmic RNA but much less in the nuclear RNA, suggesting that AFP mRNA
regulation occurs in the cytoplasm. One hypothesis regarding AFP regulation in the
cytoplasm is that the formation of AFP and asAFP dsRNA duplexes serves as a
substrate for Staufen-mediated decay, which modulates AFP mRNA stability. Future
studies to determine whether AFP mRNA stability is altered include measuring AFP
mRNA half-life in the presence or absence of robust levels of asAFP RNA. Alternatively,
Staufen-mediated mRNA decay mechanism can be explored by measuring changes in
AFP mRNA levels after siRNA knockdown of Stau1 binding protein.
To complement our overexpression studies, knockdown of asAFP RNA using
both siRNA and antisense oligos (ASO) will help distinguish whether the regulation
occurs in the cytoplasm or the nucleus. Because asAFP RNA is expressed in low
abundance in our cell culture system, I made several attempts to generate stable cells
lines expressing asAFP to carry out loss of function studies. However, I was not able to
generate cell lines that expressed asAFP RNA above background levels. This is possibly
due to clonal selection of low asAFP expressing cells or false-positives during the
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selection process. To address this limitation, monoclonal selection may ensure that high
expressing clones are obtained. In addition, it will be important to determine whether the
results obtained with cultured cell lines reliably reflect regulatory events in mice.
Because developmental silencing of AFP cannot be replicated in tissue culture cells,
animal models are essential for a full understanding of regulatory mechanisms. To
further investigate asAFP regulation of AFP in a mouse model, future studies will use
recombinant adeno-associated viral vector, rAAV8 to overexpress asAFP or knock-down
endogenous asAFP by noninvasive tail-vein injection of AAV8 vectors expressing the
sequences that were shown to have maximal function in tissue culture cells, such as
asAFP mid or exon 12 (-). From these studies, I anticipate an inverse correlation of AFP
mRNA levels when asAFP RNA is manipulated. These mouse studies may establish a
biological role for asAFP in regulating AFP expression and may provide additional
insight into the mechanism of developmentally regulated AFP expression.
While this project began with observed differences in AFP mRNA expression in
the presence or absence of Zhx2, data in this dissertation identified a functional role of
novel asAFP transcripts in regulating AFP expression. While not shown in this work, I
tested whether co-expression of asAFP RNA and Zhx2 would further regulate AFP
mRNA. Since Zhx2 and asAFP regulate AFP expression independently, I proposed that
asAFP and Zhx2 would together further downregulate AFP mRNA; for example perhaps
Zhx2 could facilitate asAFP:AFP dsRNA formation. When the asAFP mid construct was
co-transfected with as FLAG-epitope tagged Zhx2 (FLAG-Zhx2) expression plasmid, I
did not observe a greater effect on AFP downregulation. Because AFP continues to be
a clinically relevant biomarker for HCC, it is important that we understand all aspects of
AFP regulation during development and disease. The identification of asAFP as a
regulator of AFP adds an additional level of the coupled transcriptional and post-
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transcription regulation of AFP and contributes to the current understanding of cell
regulatory and disease mechanisms mediated by lncRNAs.
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APPENDIX A
LIST OF ABBREVITIONS

aa
ADAR
Afm
AFP
Afr1
Alb
alpha-1-antitrypsin
ANRASSF1
antisense non-coding RNA in the INK4 locus
Arg
AS Uchl1
asAFP
ASO
A-to-I
BACE1-AS
bp
BRE
C/EBP
CPAT
CPC
CREB
CTNNB1
CYP
DMEM
DBP
DPE
dsRNAs
endo-si RNA
eRNAs
ES
GFP
GPC3
H3K36me3
H3K4me3
HBV
HCC
111

amino acid
adenosine deaminases that act of RNA
Afamin
Alpha fetoprotein
Alpha-fetoprotein regulator 1
Albumin
alpha 1 antitrypsin
antisense intronic noncoding RASSF1
ANRIL
AFP-related gene
ubiquitin carboxy-terminal hydrolase L1
antisense alpha-fetoprotein
antisense oligos
adenosines to inosines
antisense transcript for β-secretase-1
base pairs
TFIIB recognition element
CCAAT/enhancer-binding protein beta
Coding-Potential Assessment Tool
Coding-Potential Calculator
cAMP response element binding
protein
β-catenin
cytochrome P450
Dulbecco’s minimal eagle’s media
Vitamin D-binding protein
downstream promoter element
double stranded RNAs
endogenous small interfering RNA
enhancer-derived RNAs
embryonic stem
Green Fluorescent protein
Glypican 3
histone H3 lysine 36 trimethylation
histone H3 lysine 4 trimethylation
hepatitis B
Hepatocellular carcinoma

HCV
HEK 293
Hep3B
Hepa 1.6
HepG2
HNFs
HNF4a
HULC
Igf2r
Inr
lncRNA
Lpl
MEG3
MERV
miRNA
MTE
Multiz
Mup
NAFLD
NATs
NF1ona
NRT
NTC
ORFs
Piwi RNA
PRC2

RACE

hepatitis C
Human Embryonic Kidney 293
human hepatoma
mouse hepatoma
human hepatoma
hepatic nuclear factors
Hepatocyte nuclear factor 4 alpha
highly upregulated in liver cancer
Igf2 receptor
initiator
Long noncoding RNA
Lipoprotein lipase
maternally expressed gene 3
mouse endogenous retroviral element
microRNA
motif ten element
multiple sequence alignment track
mouse urinary protein
non-alcoholic fatty liver disease NAFLD
Natural antisense transcripts
Nuclear factor 1 alpha
no reverse transcription
no template control
open reading frames
piRNAs
Polycomb repressive complex 2
protein kinase cAMP-activated catalytic
subunit beta
Rapid Ampliﬁcation of Complementary
DNA Ends

raf

regulator of AFP

RevErbα
RNA pol II
RNA-seq
SMD
SNPs
TAFs
TBP
TCF4

Rev-ErbA alpha
RNA polymerase II (pol II)
RNA-sequencing
STAU1-mediated decay
single nucleotide polymorphisms
TBP-associated factors
TATA box binding protein
Transcription Factor 4

PRKACB
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TFs
TFIID
TRα

transcription factors
transcription factor for RNA
polymerase II D
thyroid hormone receptor alpha gene

TSS
Xist
Zhx2
4f-rnp
1/2-sbsRNAs

transcriptional start sites
X-inactive specific transcript
Zinc-fingers and homeoboxes 2
RNA-binding protein 4F
1/2-Staufen binding site RNAs
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